Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AURORA MOVING TO NASDAQ?!
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/03/05/ACB-ACBFF-Aurora-Cannabis-Chief-Corporate-Officer-Hints-at-a-Move-to-Nasdaq
Last week, Cronos Group Inc. (TSXV:CRON) (NASDAQ:CRON) made cannabis industry history when the company up-listed its U.S. shares from the OTC markets to the Nasdaq Global Market. Now that the up-listing has been completed, many marijuana investors are searching for the next company to follow in Cronos' footsteps.
While we've been combing through Nasdaq listing requirements to determine the up-listing eligibility of companies like Kush Bottles, Inc. (OTC:KSHB) and more, it looks like the Chief Corporate Officer of Aurora Cannabis Inc. (TSX:ACB) (OTC:ACBFF) may have answered the question for us.
In response to a tweet asking whether or not Aurora investors will "see [a] similar move from Aurora," Cam Battley responded, "Well, in Canada we uplisted from CSE to TSXV to TSX. And in the US from OTCQB to OTCQX. So what would be your guess? ;)"
REST OF ARTICLE: https://www.dailymarijuanaobserver.com/single-post/2018/03/05/ACB-ACBFF-Aurora-Cannabis-Chief-Corporate-Officer-Hints-at-a-Move-to-Nasdaq
Zynerba Plans Study of CBD-Based ZYN002 for Fragile X Syndrome
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/03/05/ZYNE-Zynerba-Plans-Study-of-CBD-Based-ZYN002-for-Fragile-X-Syndrome
DEVON, Pa., March 05, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced the results of a positive meeting held with the U.S. Food and Drug Administration (FDA) regarding its planned development strategy for ZYN002 in Fragile X syndrome (FXS). FXS is a rare genetic developmental disability that is the leading known cause of both inherited intellectual disability and autism spectrum disorder.
ZYN002 is the first and only pharmaceutically-produced cannabidiol (CBD) formulated as a patent-protected permeation-enhanced transdermal gel. Zynerba has received U.S. Orphan Drug designation for the use of CBD as a treatment of FXS. Currently, there are no approved therapies to treat FXS or its most common symptoms.
Based on the company’s dialogue with the FDA, the Company expects to initiate a single pivotal study mid-year 2018 to support a New Drug Application (NDA) for ZYN002 in FXS. The FDA and the Company are in agreement that the primary and key secondary endpoints for the study should assess observable behaviors in patients with FXS as reported by the caregiver using the validated Aberrant Behavior Checklist in Fragile X syndrome (ABC-FXS). If the pivotal trial meets its endpoints, approval for an indication encompassing the treatment of behavioral symptoms associated with Fragile X syndrome may be granted.
“The FDA meeting was an important milestone for us as we advance the development of ZYN002 for patients and their families suffering with the profound behavioral symptoms of Fragile X syndrome,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “We are pleased with the outcome of the discussion and the guidance on trial design, and believe we now have a path forward to advance the development of ZYN002 to an NDA. We look forward to initiating the pivotal study mid-year, and potentially providing FXS patients and their families an effective and well tolerated therapy to treat the complex behavioral symptoms of Fragile X syndrome.”
Zynerba plans to initiate a pivotal 14-week randomized, double blind, placebo controlled clinical trial in approximately 200 pediatric and adolescent patients in the U.S., Australia and New Zealand. Patients will be randomized 1:1 to receive either one of two weight based doses of ZYN002, or one of two matching administrations of placebo. Zynerba anticipates initiation of this pivotal clinical trial mid-year 2018. Additional protocol details will be shared at that point. All patients will be eligible to enroll in a 12-month open label extension after completing dosing in the pivotal study.
“We believe that ZYN002 may address core behavioral symptoms of FXS and improve the quality of life for patients and their families,” said Dr. Liza Squires, Zynerba’s Chief Medical Officer. “There are currently no drugs indicated to address behavioral symptoms in the FXS population. We believe we have designed an efficient pivotal program that includes endpoints that measure clinically relevant and observable behaviors in patients with FXS, and if successful, positions us to bring the FXS community its first targeted treatment designed with patients’ symptoms in mind.”
About Fragile X syndrome
Fragile X syndrome is a rare genetic developmental disability that is the leading known cause of both inherited intellectual disability and autism spectrum disorder, affecting 1 in 3,600 to 4,000 males and 1 in 4,000 to 6,000 females. It is the most common inherited intellectual disability in males and a significant cause of intellectual disability in females. It is caused by a mutation in the Fragile X Mental Retardation gene located on the X chromosome and leads to dysregulation of the endocannabinoid pathway including the reduction in endogenous cannabinoids (2-AG and anandamide). The disorder negatively affects synaptic function, plasticity and neuronal connections, and results in a spectrum of intellectual disabilities, social anxiety and memory problems. In the US, there are about 71,000 patients suffering with FXS.
About Our Technology
Cannabinoids are a class of chemical compounds found in the Cannabis plant. The two primary cannabinoids contained in Cannabis are cannabidiol, or CBD, and ?9-tetrahydrocannabinol, or THC. Clinical and preclinical data support the potential for CBD in treating epilepsy and Fragile X syndrome, and THC has positive effects on treating symptoms of Tourette Syndrome. Zynerba is developing therapeutic medicines that utilize innovative transdermal technologies that, if successful, may allow for sustained and controlled delivery of therapeutic levels of CBD and THC. Transdermal delivery of cannabinoids may have benefits over oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream. This avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and improved safety profile. Transdermal delivery also avoids the gastrointestinal tract, lessening the opportunity for GI related adverse events and the potential degradation of CBD by gastric acid into THC, which may be associated with unwanted psychoactive effects. Using an established pharmaceutical process for manufacturing, Zynerba replicates the CBD and THC found in the Cannabis plant. We believe that this will allow us to meet stringent global regulatory agencies’ standards while ensuring that we can efficiently supply the amount of product required to meet the demand of the large markets that we are targeting.
About ZYN002
Zynerba’s ZYN002 CBD gel is the first and only pharmaceutically-produced CBD formulated as a patent-protected permeation-enhanced transdermal gel and is being studied in children and adolescents with Fragile X syndrome and developmental and epileptic encephalopathies, and in adult epilepsy patients with focal seizures. ZYN002 is a clear, permeation-enhanced gel that is designed to provide controlled drug delivery transdermally with once- or twice-daily dosing.
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric diseases with high unmet medical needs. We are dedicated to improving the lives of people with severe health conditions by developing cannabinoid medicines designed to meet the rigorous efficacy and safety standards established by global regulatory agencies. Through the discovery and development of these potentially life-changing medicines, Zynerba seeks to improve the lives of patients battling severe, chronic health conditions including Fragile X syndrome, refractory epilepsies, Tourette Syndrome, and other neuropsychiatric disorders. Learn more at www.zynerba.com and follow the Company on Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. For example, there can be no guarantee that the Company will obtain approval for ZYN002 from the U.S. Food and Drug Administration (FDA) or foreign regulatory authorities; even if ZYN002 are approved, the Company may not be able to obtain the label claims that it is seeking from the FDA. In addition, the Company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the success, cost and timing of the Company’s product development activities, studies and clinical trials; the success of competing products that are or become available; the Company’s ability to commercialize its product candidates; the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates; and the Company’s expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates. This list is not exhaustive and these and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Namaste Submits Affirmation of Readiness to Health Canada
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/03/05/N-NXTTF-Namaste-Submits-Affirmation-of-Readiness-to-Health-Canada
VANCOUVER, British Columbia, March 05, 2018 (GLOBE NEWSWIRE) -- Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTC:NXTTF) is pleased to announce that the Company’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”) has submitted its Affirmation of Readiness (“AOR”) and video evidence package to Health Canada. Cannmart is a late-stage applicant for a medical cannabis “sales-only” license under Canada’s Access to Cannabis for Medical Purposes Regulation (“ACMPR”). The purpose of the AOR is to provide evidence to Health Canada that Cannmart has completed construction and fit-up of the facility as per the application. Having submitted the AOR, the Company anticipates Health Canada’s review of the evidence package in due course and the issuance of its ACMPR sales license shortly thereafter. The AOR represents a significant milestone for the Company in completion of the construction of Cannmart’s facility.
Management Commentary
Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to have completed construction of Cannmart and submission of the AOR. Namaste is looking forward to launching Cannmart and following through with our strategy to become Canada’s leading innovator in medical cannabis online retail. Thank you to the management team at Cannmart for seeing this project through to completion and we’re looking forward to receiving follow up from Health Canada soon.”
About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis sales license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.
On behalf of the Board of Directors
“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastetechnologies.com
Further information on Namaste and its products can be accessed through the links below:
namastetechnologies.com
namastevapes.ca
everyonedoesit.ca
namastevaporizers.co.uk
everyonedoesit.co.uk
australianvaporizers.com.au
Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.
Invictus' AB Laboratories and AB Ventures Reach Important Milestones
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/03/05/IMH-IVITF-Invictus-AB-Laboratories-and-AB-Ventures-Reach-Important-Milestones
Vancouver, BC -- Mar. 5, 2018 -- / D.M.O. Newswire / -- Invictus MD Strategies Corp.'s ("Invictus" or the "Company") (TSXV:IMH) (OTC:IVITF) (FRA:8IS1) AB Laboratories Inc. ("AB Labs") is pleased to announce the closing of the acquisition of the land and building (the "Property") next door for $5.2 million for its Phase 2 expansion. The address of the Property has been consolidated with AB Labs existing address to allow the existing cultivation and sales license to extend to the Property. The milestone allows AB Labs to continue moving ahead with its aggressive cannabis production capacity, as Canada marches towards full legalization during 2018.
"Acquiring and consolidating these facilities at AB Labs has been of keen importance and we are delighted to formally secure the merging of the facilities and to begin the next steps towards delivering AB Labs to full production," said Dan Kriznic, Chairman and CEO of Invictus.
The Phase 2 construction adds 40,000 square feet to AB Labs existing 15,600 square feet of cultivation space and is on track for a mid June 2018 completion. The combined 55,600 square feet facility contains multiple rooms for cultivation, trimming and drying in a controlled and regulated environment, and plays a critical role in Invictus' strong production profile.
At the same time, construction planning moves ahead at AB Ventures Inc. (AB Ventures), located on a 100-acre property near Hamilton. The building team at AB Ventures is now completing all conditions required by the municipality, including a hydrological survey. Immediately following the completion of all of the required documentation, AB Ventures will submit building permit requests.
Once AB Ventures receives its Access to Cannabis for Medical Purposes Regulation (ACMPR) license, the entire property will have the potential for cannabis cultivation. Invictus has committed $5.5 million in funding to build out the first 21,000 square foot building on property.
About Invictus MD Strategies Corp.
Invictus MD Strategies Corp. is focused on two main verticals within the Canadian cannabis sector, namely the Licensed Producers under the ACMPR, being its 100% investment in Acreage Pharms Ltd., located in West-Central Alberta, and 50% investment in AB Laboratories Inc., located near Hamilton, Ontario which has both its cultivation and sales license under ACMPR. In addition to ACMPR licenses the Company has an 82.5% investment in Future Harvest Development Ltd. a Fertilizer and Nutrients manufacturer based in Kelowna, British Columbia.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
Dan Kriznic
Chairman & CEO
Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676
Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including the granting of a license under the ACMPR to AB Ventures are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that AB Ventures will satisfy all conditions for and be granted a license under the ACMPR and will receive a development permit on the expected terms, AB Ventures is able to successfully build a production facility, and that the legalization of recreational use of cannabis in Canada will occur as expected. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that AB Ventures will not be granted a license under the ACMPR or will not receive a development permit on the expected terms or at all, that AB Ventures is not able to successfully build a production facility, and that the legalization of recreational use of cannabis in Canada will not occur at all or as expected. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Emerald Health and Village Farms Venture Receives Cultivation License
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/03/05/EHT-EMHTF-VFF-VFFIF-Emerald-Health-and-Village-Farms-Announce-Cultivation-License
VANCOUVER, British Columbia, March 05, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV:EHT) (OTC:EMHTF) and Village Farms International, Inc. (Village Farms) (TSX:VFF) (OTC:VFFIF) today announced that Health Canada has issued a Cultivation Licence for their co-owned Delta 3 greenhouse operation (the “Joint Venture”) under Canada’s Access to Cannabis for Medical Purposes Regulations ("ACMPR"). This optimally-designed 1.1 million ft2 cannabis growing facility is located in one of the best growing climates in Canada in Delta, BC, and is conservatively projected to produce 75,000 kg of quality cannabis annually at full production.
Village Farms and Emerald aim for the Joint Venture to be one of the most consistent and reliable suppliers of quality cannabis products to wholesalers, distributors and retailers across Canada and internationally, with the goal to be the low-cost cannabis Canadian producer at an all-in production cost of less than $1.00 per gram at full production.
The Joint Venture will immediately begin cultivating cannabis in the Delta 3 greenhouse following the transfer of existing starter plants from Emerald and expects to receive its Sales License under ACMPR by July 1, 2018.
“Our Joint Venture is well positioned to be a leading supplier in the imminent legal adult-use Canadian cannabis market, with potentially significant benefit to each of our companies and our shareholders,” said Avtar Dhillon, MD, Executive Chairman of Emerald. “With Emerald’s in-depth cannabis expertise, Village Farms’ know-how based on innumerable crop cycles over 30 years of large-scale greenhouse growing, and working with global agricultural leaders and high-tech facilities and systems experts, we configured this greenhouse for continuous weekly harvesting year-round, maximum operating efficiencies, and flexibility to adapt to an evolving market. We are accomplishing this on a very capital-efficient basis.”
“Growing any agricultural crop on a large scale and repeatedly delivering expected quantities and consistent quality, with full regulatory compliance, at a competitive price is an extremely challenging proposition for even the most experienced agricultural producers. The goal is for the Joint Venture to set the standard in this regard in the Canadian cannabis industry and establish itself as a preferred supplier for both the short- and long-terms,” said Michael DeGiglio, CEO, Village Farms International. “In addition to production ramp-up, in 2018 the Joint Venture will focus on product development and developing its marketing strategy to become a vertically integrated leader in the Canadian cannabis market.”
The Joint Venture is converting the Delta 3 greenhouse operation to cannabis production with meticulous attention to the growing environment and systems, processing areas, and production ramp-up, with a particular focus on management of climate and contaminants, optimizing yield, maximizing efficiencies, and achieving continuous year-round production. Key elements of the design, conversion, and operations include:
Growing system with automation proven in different crops to provide optimal efficiencies;
Industry-leading HVAC systems reflecting hundreds of aggregate years of climate management experience, with technically advanced data systems;
High-tech light deprivation and light supplementation systems with individual control of over 15 growing zones within the 1.1 million ft2 footprint;
Fully automated 90,000 square feet nursery capable of supplying Delta 3 (as well as the 1.1 million ft2 Delta 2 facility should the Joint Venture exercise its option to purchase that facility, as described below);
State of the art drying, trimming and packaging areas;
Core upgrades to facility infrastructure;
Use of an established labour force and proprietary labour tracking systems; and,
Secure supply of low-cost electricity from BC Hydro sufficient to power Delta 3 at full production (and, if required, to power the Delta 2 facility at full production).
Conversion of the first 250,000 ft2 section of the 1.1 million ft2 Delta 3 greenhouse to cannabis production is substantially complete and is expected to commence production in April 2018. Senior growing and operational personnel, including the established team transferred from Village Farms, are in place for production ramp up. Conversion of the remainder of the 1.1 million ft2 is underway and the entire facility is expected to be in production in 2019.
The Joint Venture holds options on two additional state-of-the-art greenhouses owned by Village Farms (Delta 2 and Delta 1, with 1.1 million ft2 and 2.6 million ft2 of growing capacity, respectively). Exercising these options would expand the Joint Venture’s production facility to 4.8 million ft2 and make it one of the largest cannabis producers in Canada.
About Village Farms International, Inc.
Village Farms is one of the largest producers, marketers, and distributors of premium-quality, greenhouse-grown fruits and vegetables in North America. The food our farmers grow, along with other greenhouse farmers under exclusive arrangements are all grown in environmentally friendly, soil-less, glass greenhouses. The Village Farms® brand of fruits and vegetables is marketed and distributed primarily to local retail grocers and dedicated fresh food distributors throughout the United States and Canada. Since its inception, Village Farms has been guided by sustainability principles that enable us to grow food 365 days a year that not only feeds the growing population but is healthier for people and the planet. Village Farms is Good for the Earth® and good for you.
About Emerald Health Therapeutics
Emerald Health Therapeutics, Inc. (TSX-V:EMH) (OTCQX:EMHTF) operates through Emerald Health Therapeutics Canada Inc. ("EHTC"), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Through EHTC, Emerald is authorized to produce and sell dried cannabis and cannabis oil for medical purposes. It operates an indoor facility in Victoria, BC, and is building a 500,000 ft2 greenhouse on 32 acres in Metro Vancouver, with expansion potential to 1 million ft2 to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald owns 50% of a Joint Venture with Village Farms International, Inc. that is converting an existing 1.1 million ft2 greenhouse in Delta, BC to grow cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald is part of the Emerald Health Group, which is broadly focused on developing pharmaceutical, botanical and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more information or contact:
Robert Hill
CFO
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca
Ray Lagace
Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".
We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.
Forward-looking statements include, but are not limited to statements with respect to build out of the Company’s growing facility and the details thereof; rapid production capacity expansion; estimates of production of cannabis at the Initial greenhouse and the additional facilities discussed herein; the development and potential size of a non-therapeutic adult-use market for cannabis and cannabis extracts; contributions of cash to the JV; the JV becoming one of the world’s premier greenhouse cannabis growers; and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.
Emerald Health Therapeutics Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, failure of the federal government to approve legislation legalizing sales of non-therapeutic adult-use cannabis; failure to obtain Health Canada and other regulatory approvals; failure to obtain necessary financing; results of production and sale activities; the Company's historical experience with medical marijuana operations; results of scientific research; uninsured risks; regulatory changes; difficulties in construction or in obtaining qualified contractors to complete construction or conversion of facilities; availability of production facilities; timeliness of government approvals and the granting of permits and licenses; changes in prices and costs; actual operating and financial performance of facilities; equipment and processes relative to specifications and expectations; as well as the other risk factors set out in the Company’s annual information form and other filings with the applicable Canadian securities regulators, which may be viewed at www.sedar.com. Actual results may differ materially from those expressed or implied by such forward-looking statements.
Cronos Group Changes TSXV Trading Symbol to CRON
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/03/05/MJN-CRON-Cronos-Group-Changes-TSXV-Trading-Symbol-to-CRON
TORONTO, March 5, 2018 /CNW/ - Cronos Group Inc. (NASDAQ:CRON) (TSXV:MJN) ("Cronos Group" or the "Company") is pleased to announce that the Company is changing its ticker on the TSX Venture Exchange from MJN to CRON.
This change is effective immediately for trading commencing on Monday, March 5 and is being made to conform to the ticker symbol that was selected when Cronos Group became the first pure-play cannabis company to trade on the Nasdaq on February 27, 2018.
About Cronos Group
Cronos Group is a globally diversified and vertically integrated cannabis company with a presence across four continents. The Company operates two wholly-owned Canadian Licensed Producers regulated under Health Canada's Access to Cannabis for Medical Purposes Regulations: Peace Naturals Project Inc. (Ontario), which was the first non-incumbent medical cannabis license granted by Health Canada, and Original BC Ltd. (British Columbia), which is based in the Okanagan Valley. The Company has multiple international production and distribution platforms including: Cronos Israel and Cronos Australia. Through an exclusive distribution agreement, Cronos Group has access to over 12,000 pharmacies in Germany. The Company is rapidly expanding its global footprint as it focuses on building an international iconic brand portfolio and developing disruptive intellectual property. Cronos Group is committed to building industry leading companies that transform the perception of cannabis and responsibly elevate the consumer experience.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements, by their nature, require the Company to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements. Words such as "may", "will", "would", "could", "expect", "believe", "plan", "anticipate", "intend", "estimate", "continue", or the negative or comparable terminology, as well as terms usually used in the future and the conditional, are intended to identify forward-looking statements. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection. The Company considers its assumptions to be reasonable based on information currently available, but cautions the reader that its assumptions regarding future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company and its business.
For additional information with respect to these and other factors and assumptions underlying the forward-looking statements made in this press release, refer to the Company's most recent Annual information Form filed on SEDAR. The forward-looking information set forth herein reflects the Company's expectations as at the date of this press release and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.
Tweed's First Fashion Show at Toronto Men's Fashion Week
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/03/05/TWEED-Tweeds-First-Fashion-Show-at-Toronto-Mens-Fashion-Week
TORONTO, ON, March 5, 2018 /CNW/ - Tweed Inc. ("Tweed") is proud to present a collaborative fashion show at TOM* F/W this coming week. Over the past four years, Tweed has grown and sold thousands of kilograms of legal, high-quality cannabis products to medical customers across the country, always staying true to its roots and personality as an approachable, proudly Canadian producer.
On the evening of March 9, 2018, working in collaboration with some of Canada's top clothing designers, Tweed is set to present its first ever runway show, Tweed: Fabric of Creativity, at Toronto Men's Fashion Week. The show will feature 36 designs by 18 of Canada's top talents, and will showcase the Tweed personality to a new, equally discerning audience.
Tweed: Fabric of Creativity will showcase the immense talents of designers Zane Barlas, NICO, Xian, Pascal Labelle, Candace Daniela, Tristan Licud, Nabeel Sheikh, JM Trends, Joseph Tassoni, Shelli Oh, Kristian Nielsen, Thomas Henry, Austen Dor, WRKDEPT, L'MOMO, Get Fresh Company, Ross Mayer, and FARLEY CHATTO.
The designers and their teams have been tasked with creating ensembles that combine both tweed fabric as well as their interpretation of the essence of the Tweed brand for the runway show.
The fashion show is just one component of Tweed's participation in Toronto Men's Fashion Week. For the duration of TOM* (March 9 to 11, 2018), as well as its sister event, Toronto Women's Fashion Week (March 12 to 14, 2018), Tweed will have an on-site informational exhibit so that the adult, fashion community can get to know who we are as Canadian leaders and proud cannabis connoisseurs.
Tweed was founded with the belief that cannabis can be a force for good. Not something that should be hidden, but something which deserves informed, open dialogue. Whether through doctor education, our celebrated Artists in Residence program, or fashion week, Tweed supports the communities in which it is present.
"With brand names like Argyle and Herringbone, we are excited to finally engage with the diverse and creative fashion community to bring our personality to life, enriching the fabric of Tweed through dialogue and engagement," said Bruce Linton, co-founder and CEO of Tweed. "This is an exciting time and an exciting project for Tweed."
Tweed: Fabric of Creativity takes place Friday, March 9, 2018 at 9pm during Toronto Men's Fashion Week at 1 Yonge Street.
About Tweed
Tweed is a wholly owned subsidiary of Canopy Growth Corporation (TSX:WEED) and a globally recognized cannabis production brand. It has built a large and loyal following by focusing on quality products and meaningful customer relationships. Tweed doesn't just sell cannabis, it facilitates a conversation about a product we've all heard about but haven't met intimately yet. It is approachable and friendly, yet reliable and trusted. As cannabis laws liberalize around the world, Tweed will expand its leading Canadian position around the globe. Learn more at www.tweed.com.
Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, its subsidiaries, or its affiliates to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection. The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.
InMed to Leave CSE for the Toronto Stock Exchange
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/03/02/InMed-to-List-on-The-Toronto-Stock-Exchange?utm_campaign=4abffdbe44-EMAIL_CAMPAIGN_2017_08_28&utm_medium=email&utm_source=D.M.O.%2BNewsletter&utm_term=0_75e1ee9d7e-4abffdbe44-71132567
VANCOUVER, March 2, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE:IN) (OTC:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to list its common shares ("Common Shares") on the TSX. Final approval of the listing on the TSX remains subject to InMed fulfilling certain customary listing conditions of the TSX on or before the TSX-imposed deadline of May 29, 2018. The Company expects that it will satisfy such conditions in advance of the TSX-imposed deadline. Upon listing on the TSX, the Common Shares will continue to trade under the symbol 'IN'.
"Graduating to the TSX is a significant accomplishment for InMed," said Eric A. Adams, CEO & President. "This milestone furthers our corporate goal of securing a leadership position in this high-growth sector. InMed is one of only a few pure-play cannabinoid biopharmaceutical companies to be trading on one of the world's senior stock exchanges."
In connection with the listing of the Common Shares on the TSX, InMed will make application to the Canadian Stock Exchange ("CSE") to voluntarily delist the Common Shares from the CSE. Such delisting will be effective as of the date the Common Shares commence trading on the TSX.
Shareholders are not required to exchange their stock certificates or take any other action in connection with the TSX listing, as there will be no change in the trading symbol or CUSIP for the Common Shares.
About InMed:
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics platform, its biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: the listing of the Common Shares on the TSX subject to the fulfillment of the standard listing conditions of the TSX; the expected timing for the completion of the listing and commencement of trading of the Common Shares on the TSX; the trading symbol for the Common Shares on the TSX; InMed making application to delist the Common Shares from the CSE and the expected timing of the delisting from the CSE; and, the expected fundamental value drivers of the Company.
With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: InMed will be able to satisfy the TSX's standard listing conditions and the listing of the Common Shares on the TSX and delisting from the CSE will be completed in accordance with the timing currently expected. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: InMed may not be able to satisfy the TSX's standard listing conditions in accordance with the timing currently expected or at all; the listing may not be completed; and, InMed may not realize any benefits from listing on the TSX currently expected or anticipated by management; A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed's most recent Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Abattis Completes Gabriola Green Farms Acquisition
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/03/02/ATT-ATTBF-Abattis-Completes-Gabriola-Green-Farms-Acquisition?utm_campaign=4abffdbe44-EMAIL_CAMPAIGN_2017_08_28&utm_medium=email&utm_source=D.M.O.%2BNewsletter&utm_term=0_75e1ee9d7e-4abffdbe44-71132567
VANCOUVER, British Columbia, March 02, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce that, further to its news release dated February 27, 2018, it has completed its acquisition (the “Acquisition”) of a 90% ownership interest in Gabriola Green Farms Inc. (“Gabriola”).
Gabriola is a British Columbia company that has applied for a license to produce (an “LP”) under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) on Gabriola Island, one of the gulf islands located in the Strait of Georgia off the coast of British Columbia. Gabriola Island has a consistent temperature and humidity level, which makes it well suited to greenhouse growing.
“We are excited to complete our acquisition of Gabriola. Gabriola’s anticipated LP will complete our suite of downstream offerings and be the highlight of our growth into a full-service cannabis company,” stated Rob Abenante, Abattis President and CEO.
Gabriola currently has plans for an approximately 26,000 square-foot production facility to produce medical-grade marijuana located on 18 acres in the agricultural land reserve on Gabriola Island, BC. The facility will include a level 8 security vault.
Gabriola’s production facilities are expected to be constructed in two phases:
Phase 1 - Buildout of its 6,000-square-foot state-of-the-art facility, consistent with ACMPR standards.
Phase 2 - Upon completion of the Phase 1 buildout, Gabriola will build out an expansion of approximately 20,000 square feet.
In connection with the Acquisition, the Company issued an aggregate of 61,307,902 common shares of the Company and paid $2.5 million in cash to the shareholders of Gabriola. In connection with the Acquisition, Abattis has also secured (i) a right of first refusal on the remaining 10% ownership interest in Gabriola from CannaNUMUS Blockchain Inc. and (ii) an option to acquire the lands on which Gabriola’s operations are conducted for $7 million until February 27, 2023 from an unrelated third-party.
About Abattis Bioceuticals Corp.
Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com
ON BEHALF OF THE BOARD OFABATTIS BIOCEUTICALS CORP.,
"Rob Abenante"
Robert Abenante, President & CEO
For more information, please visit the Company's website at: www.abattis.com
For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", “intends”, "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding: Gabriola’s LP application and the expected effect the LP, once received, will have on Abattis’s business profile and offerings; Gabriola’s plans for an approximately 26,000 square foot production facility, including respecting the two expected phases of such buildout. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that Gabriola’s application for an LP will be unsuccessful; that, once received, the effect of Gabriola’s LP on Abattis’s business profile and offerings will not be as expected; that Gabriola’s construction plans will not come to fruition or will not be carried out as expected; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company’s competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company’s control. Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CannTrust to Trade on the Toronto Stock Exchange
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/03/02/TRST-CNTTFCannTrust-Starts-Trading-on-The-Toronto-Stock-Exchange?utm_campaign=4abffdbe44-EMAIL_CAMPAIGN_2017_08_28&utm_medium=email&utm_source=D.M.O.%2BNewsletter&utm_term=0_75e1ee9d7e-4abffdbe44-71132567
VAUGHAN, ON, March 2, 2018 /CNW/ - CannTrust Holdings Inc. (CSE:TRST) (OTC:CNTTF) ("CannTrust" or the "Company"), a licensed producer of medical cannabis under the Health Canada Access to Cannabis for Medical Purposes Regulation ("ACMPR") program, is pleased to announce that common shares of the Company will commence trading on the Toronto Stock Exchange (the "TSX") effective on Monday March 5, 2018. Shares will continue to trade under the symbol "TRST". In conjunction with the listing on the TSX, the common shares of the Company will be voluntarily delisted from the CSE, effective close of trading today Friday March 2, 2018.
"Graduating to the TSX reflects the amazing progress we have made since listing on the CSE in August last year and represents yet another important milestone for CannTrust as we continue our successful journey as one of Canada's leading cannabis companies" said Eric Paul, Chief Executive Officer of CannTrust.
CannTrust's listing on the Canadian Securities Exchange played an important role in the publicly recognized growth of the Company and this new listing on the TSX will allow a whole new category of investors to participate in the CannTrust story.
About CannTrust™
Since its inception in 2014, CannTrust has led the Canadian market in producing pharmaceutically standardized product.
As a federally regulated licensed producer, CannTrust™ brings more than 40 years of pharmacy and healthcare experience to the medical cannabis industry. CannTrust currently operates a 60,000 square foot state-of-the-art hydroponic facility in Vaughan, Ontario, as well as the recently completed 250,000 square foot Phase 1 redevelopment of its 430,000 square foot Niagara Greenhouse Facility. The Phase 2 expansion is underway and is anticipated to be completed and in cultivation towards the middle of 2018.
CannTrust™ is committed to research and innovation, as well as contributing to the growing body of evidence-based research regarding the use and efficacy of cannabis. Our product development teams along with our exclusive global pharma partner, Apotex Inc., are diligently innovating and developing products that will make it easier for patients to use medical cannabis. We support ongoing patient education about medical cannabis and have a compassionate use program to support patients with financial needs.
Forward Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon CannTrust's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy.
Forward-looking information include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, CannTrust does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for CannTrust to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in CannTrust's Final Long Form Prospectus dated August 11, 2017 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in CannTrust's Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.
INSYS Initiates Phase 3 Clinical Trial for Treatment of Infantile Spasms
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/03/02/INSYS-Initiates-Phase-3-Clinical-Trial-for-Treatment-of-Infantile-Spasms?utm_campaign=4abffdbe44-EMAIL_CAMPAIGN_2017_08_28&utm_medium=email&utm_source=D.M.O.%2BNewsletter&utm_term=0_75e1ee9d7e-4abffdbe44-71132567
PHOENIX, March 02, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the initiation of a Phase 3 clinical trial to study cannabidiol (CBD) oral solution for the treatment of infantile spasms, a rare type of pediatric epilepsy that occurs in very young children, with the first trial site’s activation.
“We need better treatments for infantile spasms, one of the more severe and dangerous seizure disorders of early childhood,” said Shaun Hussain, M.D., a pediatric neurologist at UCLA Mattel Children’s Hospital and director of its Infantile Spasms Project. “That’s why we’re excited about this pivotal study, which has the potential to reveal a new piece of the treatment puzzle for infantile spasms.”
In previous studies, CBD—one of the main molecules in cannabis—has demonstrated sustained clinical benefits in a variety of medically refractory pediatric epilepsies, including infantile spasms, an uncommon condition estimated by the Child Neurology Foundation (CNF) to be diagnosed in about 1,200 children in the United States each year.
“We have great hope in the potential of our proprietary formulation of pharmaceutical-grade, synthetically manufactured CBD oral solution in combination with vigabatrin to offer greater seizure control to children with infantile spasms,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. “The need for more efficacious and better tolerated products to treat this devastating disorder continues to motivate us to advance this investigational therapy through the clinical and regulatory pathway.”
According to the Infantile Spasms Action Network (ISAN), a collaborative advocacy network of 25 national and international organizations convened by CNF, infantile spasms have an average age of onset of around four months, although in some cases the first seizure occurs as early as one month or as late as two years. In most cases, infantile spasms appear to be slight head drops, which belie the seriousness of the condition. Evidence shows that infantile spasms are a more serious seizure disorder than generalized convulsions.
INSYS Therapeutics recently became a member of ISAN, which hosts an annual awareness and education initiative, Infantile Spasms Awareness Week (ISAW), held Dec. 1–7.
About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.
Forward-Looking Statements
This news release contains forward-looking statements including our belief regarding the potential of our investigational CBD oral solution to become an effective treatment for infantile spasms. These forward-looking statements are based on management’s expectations and assumptions as of the date of this news release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to, risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2016 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this news release, and we undertake no obligation to publicly update or revise these statements, except as may be required by law.
Nasdaq Approves Canadian Licensed Producer Cronos for Trading
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/26/Nasdaq-Approves-Canadian-Licensed-Producer-Cronos-for-Trading
TORONTO, Feb. 26, 2018 /PRNewswire/ - Cronos Group Inc. (TSXV:MJN) (OTC:PRMCF) ("Cronos Group" or the "Company") is pleased to announce that trading of its common shares in the United States will be elevated from the Nasdaq International Designation program to the Nasdaq Global Market ("Nasdaq").
Cronos Group expects that its common shares will begin trading on Nasdaq on February 27, 2018 under the trading ticker symbol "CRON." Cronos Group will retain its listing on the TSX Venture Exchange ("TSX-V") under the symbol "MJN."
"This up listing to NASDAQ is a major corporate milestone and reflects the significant progress we have made in strengthening our corporate governance and expanding our global footprint," said Mike Gorenstein, CEO of Cronos Group. "We believe this will increase long term shareholder value by improving awareness, liquidity, and appeal to institutional investors."
About Cronos Group
Cronos Group is a globally diversified and vertically integrated cannabis company with a presence across four continents. The Company operates two wholly-owned Canadian Licensed Producers regulated under Health Canada's Access to Cannabis for Medical Purposes Regulations: Peace Naturals Project Inc. (Ontario), which was the first non-incumbent medical cannabis license granted by Health Canada, and Original BC Ltd. (British Columbia), which is based in the Okanagan Valley. The Company has multiple international production and distribution platforms including: Cronos Israel and Cronos Australia. Through an exclusive distribution agreement, Cronos Group has access to over 12,000 pharmacies in Germany. The Company is rapidly expanding its global footprint as it focuses on building an international iconic brand portfolio and developing disruptive intellectual property. Cronos Group is committed to building industry leading companies that transform the perception of cannabis and responsibly elevate the consumer experience.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements, by their nature, require the Company to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements. Words such as "may", "will", "would", "could", "expect", "believe", "plan", "anticipate", "intend", "estimate", "continue", or the negative or comparable terminology, as well as terms usually used in the future and the conditional, are intended to identify forward-looking statements. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection. The Company considers its assumptions to be reasonable based on information currently available, but cautions the reader that its assumptions regarding future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company and its business.
For additional information with respect to these and other factors and assumptions underlying the forward-looking statements made in this press release, refer to the Company's most recent Annual information Form filed on SEDAR. The forward-looking information set forth herein reflects the Company's expectations as at the date of this press release and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.
Invictus’ Acreage Pharms’ Acquires 23 New Strains
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/21/Invictus-Acreage-Pharms-Acquires-23-New-Strains
Vancouver, BC -- Feb. 21, 2018 -- / D.M.O. Newswire / -- INVICTUS MD STRATEGIES CORP.’s ("Invictus" or the "Company") (TSXV:IMH) (OTC:IVITF) (FRA:8IS1) Acreage Pharms Ltd. (“Acreage Pharms”) is pleased to announce it has acquired 23 new cannabis strains. This marks an important step in Acreage Pharms’ march towards full-capacity cannabis production and sale this year.
“The acquisition of these strains broadens Acreage Pharms strain variety in preparation for the recreational market," said Dan Kriznic, Chairman and CEO of Invictus. “The timing is ideal, as our Phase 2 expansion includes 11 new flowering rooms, all of which will be needed to accommodate this welcome and dramatic expansion of strains.”
The collaboration allows Acreage Pharms to import genetics, including seed and starting material. As a result, Acreage Pharms’ already innovative and ambitious genetics breeding program is better able to offer a variety of strains that fully reflect the genetic diversity of cannabis, including its many health-enhancing properties. Once the new strains arrive at Acreage Pharms, in approximately 10 days, Acreage Pharms will begin creating and selecting specific genomes for production for medical and recreational use.
Production in the Phase 2 facility will reach 5,000 kg cannabis production per year. Phases 1 and 2 represent 40,000 square feet of growing space, and Phase 3 — which due to excellent progress on Phase 2 construction is on track for 2018 completion — will add another 80,000 square feet to Acreage Pharms canopy. The combined projects are projected to allow Acreage Pharms to produce 19,000 kg in 2018.
“Our team of plant scientists and horticultural engineers have been eagerly anticipating this exciting enlargement of our reservoir of strains,” said Kriznic. “We all remain extremely keen on offering patients and consumers a diverse suite of cannabis profiles this year.”
About Invictus MD Strategies Corp.
Invictus MD Strategies Corp. is focused on two main verticals within the Canadian cannabis sector, namely the Licensed Producers under the ACMPR, being its 100% investment in Acreage Pharms Ltd., located in West-Central Alberta, and 50% investment in AB Laboratories Inc., located near Hamilton, Ontario which has both its cultivation and sales license under ACMPR. Combined the two licenses and an expected third license under AB Ventures Inc. are expected to have an approximate annual run-rate production capacity of 76,400 kg by 2019. In addition to ACMPR licenses the Company has an 82.5% investment in Future Harvest Development Ltd. a Fertilizer and Nutrients manufacturer based in Kelowna, British Columbia.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
Dan Kriznic
Chairman & CEO
Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676
Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including the potential production capacity of AB Labs, AB Ventures and Acreage Pharms’ production facilities, the granting of regulatory approval and anticipated timing of AB Labs reaching full production capacity, the granting of a sales license under the ACMPR to AB Ventures and Acreage Pharms, Acreage Pharms’ receipt of a sales license and the success and timing of Acreage Pharms’ expansion plans, expected sales of inventory and the completion of the increase in the Company’s ownership of AB Labs pursuant to the definitive agreement (the “Transaction”) are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that AB Labs, AB Ventures and Acreage Pharms will satisfy all conditions for, and receive, regulatory approval to sell medical cannabis at their production facilities’ full capacity, AB Ventures will satisfy all conditions for and be granted a license under the ACMPR and will receive a development permit on the expected terms, AB Ventures is able to successfully build a production facility, Acreage Pharms will satisfy all conditions for and successfully obtain the anticipated sales license and will successfully complete its expansion plans, the anticipated sales of inventory will take place on the terms and timing expected by management, all conditions to the closing of the Transaction will be satisfied and the Transaction will complete on the terms set out in the definitive agreement and that the legalization of recreational use of cannabis in Canada will occur as expected. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that AB Labs, AB Ventures and Acreage Pharms will not receive regulatory approval to sell medical cannabis at their production facilities for their full production capacity or at all, that AB Labs, AB Ventures or Acreage Pharms will not reach full production capacity, that AB Ventures will not be granted a license under the ACMPR or will not receive a development permit on the expected terms or at all, that AB Ventures is not able to successfully build a production facility, that Acreage Pharms is not able to obtain the anticipated sales license when expected by management or at all or is not able to successfully complete its expansion plans, that the anticipated sales of inventory will not occur on the terms and timing expected by management or at all, that the Transaction will not complete on the expected terms or at all and that the legalization of recreational use of cannabis in Canada will not occur at all or as expected. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Affinor Growers Signs Caribbean Licensing Agreement
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/21/Affinor-Growers-Signs-Caribbean-Licensing-Agreement
VANCOUVER, British Columbia, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Affinor Growers Ltd. (“Affinor Growers”) (CSE:AFI) (OTC:RSSFF) (Frankfurt:1AF) is pleased to announce it has signed an exclusive license agreement with Vertical Designs Aruba Inc. (“VDA”) to produce marijuana and food using the Affinor Growers patented rotating vertical towers.
In return for granting the license, Affinor Growers will receive 10% ownership in VDA and VDA will order all towers from Affinor for its farm to be based in Aruba. The license granted to VDA will cover the region of the Caribbean and as VDA expands into other countries in the Caribbean and incorporates new subsidiaries, it may sub license Affinor’s technology and Affinor will receive a 10% stake in all other sub licences or subsidiaries through out the Caribbean.
Marijuana is not currently legal in Aruba, however in the event laws change we will be ready to service the Marijuana market. One of the key advantages to growing plants using the tower technology in Aruba is the favourable growing climate.
Nicholas Brusatore, CEO commented that, “I am very excited about the new agriculture market we are about to access in the Caribbean, this will bring Affinor’s technology, additional jobs and training for Aruba.”
About Affinor Growers
Affinor Growers is a publicly traded company on the Canadian Securities Exchange under the symbol ("AFI"). Affinor is focused on growing high quality crops such as romaine lettuce, spinach, strawberries using its vertical farming techniques. Affinor is committed to becoming a pre-eminent supplier and grower, using exclusive vertical farming techniques.
Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain assumptions, estimates, and other forward-looking statements regarding future events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.
Veritas Pharma Provides Corporate Update on Q1 2018
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/21/Veritas-Pharma-Provides-Corporate-Update-on-Q1-2018
VANCOUVER, British Columbia, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to provide an official corporate update on its achievements, related scientific activities and growth strategies for the first quarter of fiscal 2018.
New Laboratory Space
The Company is presently looking at prospective office and research lab space on the campus of the University of British Columbia (“UBC”) with the aim of expanding its operations in Q3 of this year.
Product Pipeline and Human Trials
In January 2018, Veritas' subsidiary, Cannevert Therapeutics Ltd. (“CTL”), signed a clinical research agreement with Puerto Rico’s Fundación de Investigación (“FDI”) to perform human trials of its lead cannabis strain, CTL-X, for targeting pain management. Since then, FDI has prepared submissions as well as made formal presentations about the proposed study design to local regulatory authorities. It is anticipated that approvals for the conduct of this study will come at the end of Q1 2018 with its immediate start in Q2 2018. The Institute for Medical Cannabis Corporation (“IMC”) of Puerto Rico is still on track to provide CTL with the necessary placebo and specific cannabis strain for the upcoming human studies at FDI.
Health Canada Dealer Licence
In December 2017, Veritas announced that Health Canada had issued its subsidiary CTL a dealer licence (no. 2018/6970) under Health Canada’s Section 9.2 of the Narcotic Control Regulations (“NCR”). This will allow CTL to possess, produce, analyze, sale, send, transport, and deliver cannabis, hemp and related products and to be a commercial service provider of chemistry and biological testing services for licensed producers under Health Canada guidelines. Since then, Cannevert has been working to obtain more diverse cannabis strains from various parts of the World to investigate their therapeutic potential. The dealer licence allows CTL to greatly accelerate its research and development and expand access to various cannabis strains with potentially therapeutic capacity.
Cannevert Therapeutics Cancer Research Project
In November 2017, the Company announced that its research arm CTL had initiated a cancer research project with Dr. Dmitri Petchkovski of Fibroblast Consulting in Vancouver, to assess the effects of several human cancer cell lines against select cannabis strains, along with standard clinical chemotherapeutic drugs for comparison. Dr. Petchkovski will specifically investigate lung, prostate, colon, breast, and melanoma cancer cell lines.
Sechelt Organic ACMPR Application
Veritas’ subsidiary, Sechelt Organic Marijuana Corp. (“SOM”), currently owns a secure commercial facility and land located in Sechelt, British Columbia, Canada. Since July 4, 2014, SOM has had an application with Health Canada to become a licensed producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). To date, SOM has moved into the fifth (Application Review) of the seven stages of the application process and subject to clearing this stage, its awaiting Pre-Licence Inspection and Licensing.
Completion of Cannevert Therapeutics Ltd. Acquisition
From inception of Veritas Pharma, CTL was established as the exclusive research arm of Veritas through 80% acquisition of CTL. Veritas Pharma recently signed an agreement with Davidson & Company LLP to assist in providing the Company with a ‘Fairness Opinion’ on the potential value of taking over the remaining 20% of CTL. Davidson will provide their opinion on whether that value is fair based on the skillsets of the Cannevert team, their scientific and clinical accomplishments, including the acquisition of a Health Canada Dealer Licence, and the current state of the medical cannabis industry. Davidson’s final report is scheduled to be delivered to Veritas by February 28, 2018.
The Company also announces the issuance of 2,000,000 stock options at $0.65 to directors, management, and consultants of the Company for a term of twelve (12) months and the cancelation of 1,000,000 previously announced stock options.
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 80% owned subsidiary Cannevert Therapeutics Ltd. ("CTL"), is advancing the science behind medical cannabis. It is the Company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical cannabis claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company's commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.
Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: veritaspharmainc.com
On behalf of the Board of Directors
"Dr. Lui Franciosi"
Dr. Lui Franciosi
President and Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com
GB Sciences Receives Issuance of Its Cannabis Oil Production License
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/21/GB-Sciences-Receives-Issuance-of-Its-Cannabis-Oil-Production-License
LAS VEGAS, Feb. 21, 2018 /CNW/ -- GB Sciences, Inc. (OTC:GBLX) has been issued its production license and now begins full production operations in the Las Vegas, Nevada facility. Production license partners include Relax With Happy™ ("RWH"), a new venture co-founded by veteran cannabis chef, Deliciously Dee™, and Cura Cannabis Solutions, maker of the best-selling cannabis brand on the West Coast, Select Oil.
Given already announced contractual arrangements with those production partners, operations are expected to generate significant monthly free cash flow after a ramp up period of approximately two months.
John Poss, CEO & Chairman of the board of GB Sciences, said: "Partnering with the right companies is important to us. In any business, but perhaps particularly in this business, philosophical harmony between partners is what makes a partnership work, and work better. We are most fortunate to have Cura with its pristine reputation and demonstrated expertise, as well as Relax With Happy™, whose hand-crafted, micro-dosed edibles will vastly improve the options available in the Nevada market."
Cameron Forni, co-founder and president of Cura Cannabis Solutions remarked, "Quality, consistency and safety are three major priorities for us here at Cura, and GB Sciences has managed to hit high marks on each of those critical points. The team's attention to detail and focus on quality makes the two companies an excellent cultural match and natural partners."
Dee Russell, Co-founder and COO of RWH said: "Relax With Happy™ products are created for those cannabis customers who want a micro-dosed edible… especially elderly patients who may need a lower dose for control of their symptoms without taking away their functionality. GB Sciences is the perfect partner for Relax With Happy™ because of their shared emphasis on standardization and full spectrum cannabis benefits. We are confident that together, we will provide novel, fun, delicious, and medically-sound edible products for the Nevada market."
Mr. Poss concluded: "We are excited by the prospect of these partnerships, and we expect first retail sales from the production facility sometime during the second quarter of 2018."
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
About Cura Cannabis Solutions
Cura Cannabis Solutions is one of the largest cannabis brands in America, on a mission to be the leading provider of cannabis oil in legal U.S. and international markets. Our goal is to provide patients and customers with the cleanest, most flavorful high quality cannabis oils, with the safest delivery method available. Makers of the Select Oil and Select CBD brands, Cura was established in Portland, Oregon in 2015 and expanded into California and Nevada in 2017, with new states on the horizon in 2018. Learn more at: www.curacan.com.
About Relax With Happy™
Chef Dee (aka, Deliciously Dee™) co-founded the Relax With Happy™ brand to provide responsibly-dosed edibles that would both treat and tantalize consumers, while helping them avoid a "bad edibles experience". Many cannabis patients also choose edibles as their preferred method for treatment, and Relax With Happy™ provides scientifically-accurate dosing in products that are delicious and "easy-to-take". Chef Dee has been making medicinal edibles with cannabis from 2006 to present. Although she is a classically trained chef, her real calling was in cannabis infusions and cannabis education. In 2014 she published the first edition of her cannabis cookbook, The Happy Chef THC, including hip-hop album "The Prescription" from hip-hop artist and MMJ patient B-Real of Cypress Hill. In 2015, Dee worked as a Canna Chef in the first licensed MMJ Production Kitchen in the state of Nevada located in the fabulous city of Las Vegas, and she continues to make her edibles for patients in Nevada today.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Canopy Growth Signs Supply and Sales Agreement with Sunniva Medical Inc
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/21/WEED-TWMJF-Canopy-Growth-Signs-Supply-and-Sales-Agreement-with-Sunniva-Medical
SMITHS FALLS, ON, Feb. 21, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) is pleased to announce the signing of a definitive supply agreement with Sunniva Inc. ("Sunniva") (CSE:SNN) (OTC:SNNVF). Through the terms of this two-year agreement, Canopy Growth will purchase up to 90,000 kilograms of dried cannabis from Sunniva's wholly-owned Canadian subsidiary, Sunniva Medical Inc., a late-stage Access to Cannabis for Medical Purposes Regulations ("ACMPR") applicant, and sister company of Natural Health Services, the sector's largest non-Licensed Producer medical patient network with tens of thousands of active registrations in the ACMPR.
The agreement will see Sunniva grow Canopy's existing line-up of award winning genetics as well as its own branded products, both for sale through Canopy Growth's extensive distribution network, including Tweedmainstreet.com, the planned Tweed retail store network across the country, and through provinces in which Canopy has already established historic supply agreements. The deal secures a diverse supply of curated cannabis products for Canopy Growth and a reliable sales channel and stream of revenue for Sunniva, with appropriate risk sharing formulas in place for both parties.
"We welcome Sunniva to the Canopy Growth family and look forward to collaborating with their team to provide a steady and high-quality source of cannabis products for consumers," said Mark Zekulin, President, Canopy Growth. "Through provincial distribution channels, brick and mortar locations, and our online Tweed Main Street e-commerce platform we are diversifying our ability to deliver a one-stop shopping experience to consumers and provincial bodies alike. With partners like Sunniva, we are well positioned to capture market share through robust supply channels."
Sunniva is developing a 700,000 sq. ft. GMP-certified greenhouse facility in British Columbia which will act as the primary production facility to meet their supply goals. The facility will produce cannabis products to supply the current medical market and the upcoming legalized recreational market in Canada.
"This agreement with Canopy Growth represents a significant milestone for us," said Leith Pedersen, President, Sunniva Inc. "Providing a supply of high-quality cannabis products through Canopy Growth's unparalleled retail and distribution channels, allows us to accelerate the execution of our business plan and distribution strategy. We plan to focus on building a sustainable and profitable business as we develop the Sunniva brand and by entering into strategic partnerships with the global industry leader Canopy Growth, we are doing just that."
Here's to Future CraftGrowth.
About Sunniva Inc.
Sunniva, through its subsidiaries, is a vertically integrated medical cannabis company operating in the world's two largest cannabis markets – Canada and California – where we are committed to delivering safe, high-quality products and services at scale. Our business vision is to become the lowest cost, highest quality cannabis producer in the markets we serve. We will accomplish this by building large scale purpose-built cGMP greenhouses, offering better quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.
About Sunniva Medical Inc.
SMI is a late stage ACMPR applicant in final review and is building the Sunniva Canada Campus, 700,000 square feet of purpose-built cGMP complaint greenhouse facilities to be located in British Columbia. The total Campus is expected to produce over 100,000 kg of premium medical cannabis a year and over 25,000 kg of trim used for extraction. The facility will produce pesticide free products and will convert trim to extracted products such as cannabis oil. The oil will be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams. Sunniva anticipates to break ground in early 2018.
About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.
Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates seven cannabis production sites with over 1 million square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The Company has operations in seven countries across four continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and through its partly owned subsidiary, Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. For more information visit www.canopygrowth.com
Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, its subsidiaries, or its affiliates to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection. The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.
IGC Reports Third Quarter Financial Results, EPS Loss of $0.02
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/20/IGC-Reports-Third-Quarter-Financial-Results-EPS-Loss-of-002
BETHESDA, Md., Feb. 20, 2018 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE:IGC) announced financial results for the third quarter ended December 31, 2017 for the fiscal year that ends March 31, 2018 (the “FYE2018 Q3”).
Revenue for fiscal Q3 2018 was $762,000 compared to $250,000 for fiscal Q3 2017. The increase in revenue is attributable to trading commodities related to infrastructure that is part of our legacy business.
Selling, general and administrative expenses were $507,000 for Q3 2018 as compared to $323,000 for Q3 2017. The majority of these expenses are associated with public company costs, and the increase is attributable largely to non-cash share grants to employees, directors, and advisors.
In Q3 2018, the Company reported a GAAP loss of $533,000 and a GAAP EPS loss of $0.02, compared to a GAAP net loss of $112,000 and a GAAP EPS loss of $0.00 for Q3 2017. The increase in loss is attributable to a one-time non-cash gain incurred in Q3 2017 and the accounting for non-cash share grants in Q3 2018. The non-GAAP cash loss in Q3 2018 is about $360 thousand.
For the period ended December 31, 2017, our cash and cash equivalents was approximately $1,691,000.
“We have three major goals for 2018 a) launch Hyalolex in 10 states, b) finalize and launch Serosapse for Parkinson’s, and c) substantially reduce or eliminate debt. Our Alzheimer’s product, Hyalolex, an industry first, is progressing as planned. Our work on formulation and packaging is complete and we expect initial commercialization as a Complementary Alternative Medicine sold via licensed medical dispensaries in select states in the near-term, as we strive to help those diagnosed with Alzheimer’s, a disease that effects over 5.5 million in the U.S, and along with associated dementia costs the economy around $260 billion. We remain confident in the value of our phytocannabinoid therapy portfolio as we look to address key indications in the emerging medical cannabis industry,” stated Ram Mukunda, CEO.
About IGC
IGC has two lines of business, a legacy infrastructure business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer’s patients. The Company recently announced that it is working on using blockchain to address issues specific to the cannabis industry that address transactional difficulties, product labeling, product identification assurance (PIA), and product origin assurance (POA). The company is based in Maryland, USA.
Our website: www.igcinc.us. Twitter @IGCIR
Forward-looking Statements:
Please see forward looking statements as discussed in detail in IGC's Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.
2 Cannabinoid Biotech Companies Presenting at the RBC Conference
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/20/2-Cannabinoid-Biotech-Companies-Presenting-at-the-RBC-Conference
With two different cannabinoid-related biotech companies set to present this week at the 2018 RBC Capital Markets Global Healthcare Conference including Insys Therapeutics, Inc. (NASDAQ:INSY) and more, we wanted to give you a head-start on which stocks to keep an eye on for later in the week.
The conference is set to take place Wednesday, February 21st through Thursday, February 22nd in New York City, with numerous companies expected to present.
It's important to pay attention whenever one of your current or prospective portfolio holdings is participating in major conferences. First and foremost, the increased awareness garnered by these conferences can move stock prices. Secondly, the companies participating usually have one of their top executives giving an overview of their company and what's to come.
Here's two cannabinoid-related pharma stocks expected to present this week, in alphabetical order:
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)
Corbus CEO Yuval Cohen, Ph.D. will be presenting in a fireside chat at the 2018 RBC Capital Markets Global Healthcare Conference on Thursday, February 22nd at 3:35 p.m. EST. Dr. Cohen will discuss the company's four clinical development programs in diffuse cutaneous systemic sclerosis, cystic fibrosis, skin-predominant dermatomyositis and systemic lupus erythematosus for lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrosis.
Insys Therapeutics, Inc. (NASDAQ:INSY)
Insys CEO Saeed Motahari and CFO Andrew Long will be presenting at the 2018 RBC Capital Markets Global Healthcare Conference on Thursday, February 22nd at 10:00 a.m. EST at the Lotte New York Palace Hotel. In addition to making a presentation, management will also provide an overview of the company’s business in one-on-one meetings with investors who are registered to attend the conference.
Be sure to subscribe to one or more of our free e-mail newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, and Instagram.
Aphria Lowers Cash and Shares Payable to Nuuvera Shareholders
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/20/Aphria-Lowers-Cash-and-Shares-Payable-to-Nuuvera-Shareholders
This morning, Aphria Inc. (TSX:APH) (OTC:APHQF) announced that it has entered into an amending agreement to the previously announced arrangement agreement with Nuuvera Inc. (TSXV:NUU) (OTC:NUUVF).
The two companies have agreed to amend the Arrangement Agreement to reduce both the required level of unrestricted cash and the consideration payable to holders of Nuuvera's common shares. The consideration under the Amendment has been reduced from $1.00 CAD in cash plus 0.3546 of an Aphria common share for each Nuuvera share to $0.60 CAD in cash plus 0.3546 of an Aphria share for each Nuuvera share.
This offers substantial savings for Aphria, while cutting back payables to Nuuvera shareholders measurable.
Aphria had previously announced in connection with the Arrangement Agreement that it had secured irrevocable hard lock ups from Nuuvera shareholders representing more than a majority of both the currently outstanding Nuuvera Shares and the "minority" Nuuvera shareholders to vote in favor of the Arrangement Agreement. In connection with the Amendment, Aphria has sought and received consent from Lock-Up Shareholders that, together with Nuuvera Shares already owned by Aphria, represent approximately 65% of the currently outstanding Nuuvera Shares and over 57% of the requisite minority shareholders of Nuuvera, to the reduction of consideration under the Arrangement Agreement.
In connection with the Amendment, the board of directors of Aphria received an opinion from its financial advisor, Cormark Securities, that, as of February 19, 2018, and subject to the assumptions, limitations and qualifications on which such opinion is based, the consideration to be offered by Aphria in respect of the Arrangement, as amended by the Amendment, is fair, from a financial point of view, to Aphria.
The completion of the transaction contemplated under the Arrangement Agreement and the Amendment is not expected to be delayed and the transaction is expected to close in April, 2018.
It should be noted that in the Frankfurt session yesterday, shares of Aphria traded up 0.27€ or 2.97% to 9.35€, which is equivalent to roughly $14.57 CAD or $11.60 USD per share. For perspective, shares of Aphria closed the Friday session in Toronto trading at $14.06 CAD per share.
To stay up to date with important developments in the cannabis industry, be sure to subscribe to one or more of our free email newsletters. Also, connect with The Daily Marijuana Observer on Facebook, Twitter, StockTwits and Instagram!
Aphria Lowers Cash and Shares Payable to Nuuvera Shareholders
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/20/Aphria-Lowers-Cash-and-Shares-Payable-to-Nuuvera-Shareholders
This morning, Aphria Inc. (TSX:APH) (OTC:APHQF) announced that it has entered into an amending agreement to the previously announced arrangement agreement with Nuuvera Inc. (TSXV:NUU) (OTC:NUUVF).
The two companies have agreed to amend the Arrangement Agreement to reduce both the required level of unrestricted cash and the consideration payable to holders of Nuuvera's common shares. The consideration under the Amendment has been reduced from $1.00 CAD in cash plus 0.3546 of an Aphria common share for each Nuuvera share to $0.60 CAD in cash plus 0.3546 of an Aphria share for each Nuuvera share.
This offers substantial savings for Aphria, while cutting back payables to Nuuvera shareholders measurable.
Aphria had previously announced in connection with the Arrangement Agreement that it had secured irrevocable hard lock ups from Nuuvera shareholders representing more than a majority of both the currently outstanding Nuuvera Shares and the "minority" Nuuvera shareholders to vote in favor of the Arrangement Agreement. In connection with the Amendment, Aphria has sought and received consent from Lock-Up Shareholders that, together with Nuuvera Shares already owned by Aphria, represent approximately 65% of the currently outstanding Nuuvera Shares and over 57% of the requisite minority shareholders of Nuuvera, to the reduction of consideration under the Arrangement Agreement.
In connection with the Amendment, the board of directors of Aphria received an opinion from its financial advisor, Cormark Securities, that, as of February 19, 2018, and subject to the assumptions, limitations and qualifications on which such opinion is based, the consideration to be offered by Aphria in respect of the Arrangement, as amended by the Amendment, is fair, from a financial point of view, to Aphria.
The completion of the transaction contemplated under the Arrangement Agreement and the Amendment is not expected to be delayed and the transaction is expected to close in April, 2018.
It should be noted that in the Frankfurt session yesterday, shares of Aphria traded up 0.27€ or 2.97% to 9.35€, which is equivalent to roughly $14.57 CAD or $11.60 USD per share. For perspective, shares of Aphria closed the Friday session in Toronto trading at $14.06 CAD per share.
To stay up to date with important developments in the cannabis industry, be sure to subscribe to one or more of our free email newsletters. Also, connect with The Daily Marijuana Observer on Facebook, Twitter, StockTwits and Instagram!
OWC Pharma Appoints a New Chief Scientific Officer
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/20/OWC-Pharma-Appoints-a-New-Chief-Scientific-Officer
This morning, OWC Pharmaceutical Research Corp. (OTC:OWCP) announced the appointment of Dr. Oron Yacoby Zeevi as its new Chief Scientific Officer.
Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry. She joined Neuroderm (NASDAQ:NDRM), a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders in 2008 as the Vice President of Research and was promoted to the position of VP R&D in 2010. From October 2016 until her recent departure, she served as Chief Scientific Officer. Neuroderm was sold to Mitsubishi Tanabe Pharma for US $1.1 billion in July 2017.
Dr. Yacoby Zeevi is the inventor of over 50 issued patents and pending patents. Her expertise lies in industry-oriented innovation and scientific research, accelerating and orchestrating the evolution of new ideas through R&D proof of concept, intellectual property development, chemistry and manufacturing controls (CMC), early efficacy and safety trials, regulatory affairs and market landscape mapping in fields of unmet medical needs. She earned her Ph.D. in microbiology and immunology from Ben Gurion University in Be'er Sheva, Israel and also holds a degree of Doctor in Veterinary Medicine from the Hebrew University of Jerusalem.
Dr. Yehuda Baruch who, will now assume the role of Chief Medical and Regulatory Officer of the OWC Pharmaceutical Research Corp. commented:
"I am very pleased that we have reached a stage in our development where we were able to recruit a scientist of the caliber and background of Dr. Yacoby Zeevi. Her past scientific experience and achievements will greatly benefit our endeavors."
Dr. Yacoby Zeevi commented, "I am very proud to join OWCP and cooperate with their excellent management team in order to advance the Company to the next level. The Company has achieved a great deal in its clinical development to date and I am sure I can help in accelerating its growth."
Mr. Mordechai Bignitz, Chief Executive Officer, commented on the appointment, "I am proud and honored to have Dr. Zeevi agree to join OWCP and assume the role of CSO. She brings with her immense pharmaceutical discovery and development knowledge, a unique set of skills and an exceptional track record, which contributed significantly to the success of her previous company. Her addition will complement our management team extremely well."
For those who are unfamiliar with OWC Pharma, through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
Canopy Growth Obtains License for First Mega-Scale BC Facility
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/20/Canopy-Growth-obtains-license-for-first-mega-scale-BC-facility
ALDERGROVE, BC, Feb. 20, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) is pleased to announce that it has received a cultivation licence for the first of its two sites operating under the BC Tweed Joint Venture Inc. ("BC Tweed") banner.
The rapid licensing of the Aldergrove site, the largest federally licensed cannabis site anywhere in the world, continues a pattern of professional execution for the Company as it prepares to meet an unprecedented increase in demand in a few short months once legal adult-use markets commence. The initial licensing covers over 400,000 sq. ft. of growing space, allowing vegetative growth so that the mature plants can be spread into the full 1.3 million sq. ft. in the coming months for flowering and ultimate harvest.
Friday was the culmination of world class execution (and not much sleep) from the Company's BC team with support from teams across the country, as in only a few short months the site was renovated with lighting, shade systems, security, and automated systems to meet the rigorous standards of both the ACMPR and Canopy Growth. Over the weekend, the site received the largest single shipment of cannabis clones in the Company's history, with over 100,000 live cannabis clones flying high from the Tweed Smiths Falls Campus to their new home in British Columbia.
"Our team has made monumental and often historic progress in the retail landscape of every Canadian province to have announced its system to date. We are the only producer in Canada who can make this claim and we will continue to leverage our production platform in order to solidify a truly national presence for our cannabis brands," said Mark Zekulin, President, Canopy Growth. "A cultivation license for our first BC Tweed site positions us to continue this trend as Canada's, and indeed the world's largest, most reliable and most diversified producer and seller of high quality regulated cannabis."
"As proud native British Columbians and long-time horticulture producers we are excited to continue the proud tradition of BC bud on a national scale," said Victor Krahn, who runs operations for BC Tweed. "Working with Canopy Growth we're going to take the Tweed brand to the next level on the West Coast and bring the best our province has to offer to the country and the world."
With the Aldergrove, BC site now into the production stage, BC Tweed's focus will turn to its second BC site, a 1.7 million sq. ft. greenhouse, with work already well under way. With this expansion, Canopy Growth is on track to have over 5.6 million sq. ft. of domestic growing space.
Management consulted IIROC and made the decision to halt trading of Canopy Growth common shares on the TSX on Friday, Feb 16th at approximately 4:20 pm ET when it learned that it had been issued the licence because it represented a material change in the Company's production capacity.
Here's to Future (Sun Grown BC Bud) Growth (from Your Friends at Tweed).
About Tweed
Tweed is a globally recognized cannabis production brand. It has built a large and loyal following by focusing on quality products and meaningful customer relationships. Tweed doesn't just sell cannabis, it facilitates a conversation about a product we've all heard about but haven't met intimately yet. It is approachable and friendly, yet reliable and trusted. As cannabis laws liberalize around the world, Tweed will expand its leading Canadian position around the globe. Learn more at www.tweed.com.
About BC Tweed Joint Venture
BC Tweed Joint Venture is a collaboration between Canopy Growth and an established, large-scale greenhouse grower to develop up to 3 million sq. ft. of high-end, automated greenhouse production space across two sites in beautiful British Columbia. Production is already underway to serve the growing demand for Canopy's family of genetics.
About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.
Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates seven cannabis production sites with over 665,000 square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The Company has operations in seven countries across four continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and through its partly owned subsidiary, Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. For more information visit www.canopygrowth.com
Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, its subsidiaries, or its affiliates to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection. The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Canopy, Delta 9 Partnership Awarded Conditional Retail License in Manitoba
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/16/Canopy-Delta-9-Partnership-Awarded-Conditional-Retail-License-in-Manitoba
This morning, the Manitoba government announced that one of four licenses to legally retail recreational cannabis in the province has conditionally been awarded to the duo consisting of Delta 9 Cannabis Inc. (TSXV:NINE) (OTC:VRNDF) and Canopy Growth Corp. (WEED:TSX) (OTC:TWMJF).
The two companies' partnership within the province was announced back in November, just a day after it was announced that the province of Manitoba wanted a “hybrid model” of private retailers with government oversight to sell legal marijuana in July.
Manitoba’s Liquor and Lotteries Corporation was tasked with obtaining the cannabis supply for the prairie province, and a series of private retail stores was going to be approved to dispense the product to consumers in store as well as online.
The license will authorize the Delta 9/Canopy Growth partners to build and operate a chain of retail stores throughout the Province of Manitoba. The first location for Delta 9 has already been constructed in the Osborne Village area of Winnipeg, and has been operating for several months as a resource center and clinic. That location will become the first of many more stores, says Delta 9 CEO John Arbuthnot.
"It is hard to overstate how important this award is for our company, our shareholders, and for the future of the legal cannabis industry in Manitoba," Arbuthnot said. "As the only Manitoba producer licensed to sell cannabis, and partnered with the world's largest cannabis company, we feel we are uniquely situated to serve the Manitoba market with both quantity and quality of product."
Delta 9 management estimates the provincial cannabis market at $300 to $500 million annually. "Having one of only four retail licenses in this market, combined with what we feel is our unmatched ability to address that market, is a huge advantage for Delta 9, and should prove to be a great boon for our shareholders," Arbuthnot said.
Arbuthnot says the agreement with Canopy Growth was reached as part of the Company's commitment to adequately supply the Manitoba market. The Company has also accelerated its own expansion of its production facility in Winnipegfollowing the closing in December 2017 of a $23 million short form prospectus bought deal offering led by Canaccord Genuity Corp.
Delta 9 is pleased to announce the construction project is coming in significantly under budget, with the cost per grow pod dropping from approximately $40,000 to approximately $28,000. The Company now believes that it is fully funded to build 600 of its self-designed 'grow pods', estimated to increase cannabis production to approximately 17,500 kilograms annually.
"We've committed to producing a baseline amount of product for the Manitoba market, and we are confident we can achieve those numbers," said Arbuthnot. "However, we would like to exceed those projections in order to not only meet demand in Manitoba, but also meet or exceed our commitments to national sales under our previously announced CraftGrow agreement with Canopy Growth."
Additionally, Delta 9 products will be distributed through Canopy Growth outlets in other provinces, and through the Tweed Main Street online sales portal (tweedmainstreet.com). As responsible existing cannabis businesses, Delta 9 and Canopy Growth plan to work collaboratively within the proposed Manitoba framework to bring locally produced products as well as the best variety from across the country to future cannabis consumers throughout the province.
To stay up to date with important developments in the cannabis industry, be sure to subscribe to one or more of our free email newsletters. Also, connect with The Daily Marijuana Observer on Facebook, Twitter, StockTwits and Instagram!
Stony Hill Corp. Investee, GemmaCert, Closes $2.25 Million Series A-1 Round
BEVERLY HILLS, CA / ACCESSWIRE / February 16, 2018 / Stony Hill Corp. (OTC:STNY) ("the Company"), a diversified company focused on the legal cannabis industry, is pleased to announce that one of its portfolio companies, GemmaCert, has completed a $2.25 Million Series A-1 financing round (the "Financing").
GemmaCert, will be using proceeds from the Financing to launch their non-destructive desktop cannabis composition and potency testing solution primarily for professional and home growers, processors and dispensaries.
REST OF ARTICLE: https://www.dailymarijuanaobserver.com/single-post/2018/02/16/Stony-Hill-Corp-Investee-GemmaCert-Closes-225-Million-Series-A-1-Round
Solaris Nutraceuticals Receives $2,500,000 AUD Grant for Greenhouse
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/15/Solaris-Nutraceuticals-Receives-AUD2500000-Grant-from-Federal-Department-of-Innovation-Industry-Science
VANCOUVER and SYDNEY, New South Wales, Feb. 15, 2018 /CNW/ - PUF Ventures Inc. ("PUF" or the "Company") (CSE:PUF) (Frankfurt:PU3) (OTC:PUFXF), an advanced Access to Cannabis for Medical Purposes Regulations ("ACMPR") license applicant, and its strategic partner MYM Nutraceuticals (CSE:MYM) are pleased to announce the Casino, New South Wales based Solaris Nutraceuticals Pty Ltd, which is building the largest medical cannabis greenhouse in the southern hemisphere, has been awarded a AUD$2,500,000 Regional Jobs Investment Program (RJIP) grant, through Federal Department of Innovation, Industry & Science,
"We are co-investing with Solaris Nutraceuticals to make sure it (the medicinal cannabis facility) happens," said Kevin Hogan, Australian Member of Parliament. "Up to 280 jobs will be there one day providing this great new product that is needed by our community. We look forward to having the largest medicinal cannabis facility in the Southern Hemisphere soon in Casino."
"We are very honoured to be awarded this Federal Grant towards the construction of our 1,200,000 sq.-f.t greenhouse," said Michael Horsfall, Co-founder and CEO of Solaris Nutraceuticals. "We have been overwhelmed with the generous support we have received from all levels of government. We are working hard to deliver this project. We expect to create upwards of 300 to 500 direct and indirect jobs in the Northern Rivers Region from our greenhouse project. This will provide a significant boost to the local economy"
The new facility will be Australia's largest growing, manufacturing, processing and research facility in Australia. This is an innovative project which will help patients, create new jobs, complete further research and develop new products in the medical cannabis field.
The company is currently in the assessment stage for three licenses with the Office of Drug Control in Canberra.
Kevin Hogan, Member of Parliament: https://m.facebook.com/story.php?story_fbid=1694316460660111&id=356113427813761&refsrc=http%3A%2F%2Ft.co%2F4LMgCG1HkD&_rdr
About Solaris Nutraceuticals Inc.
Solaris Nutraceuticals is an innovative medical technology company headquartered in Sydney, Australia. The Company is owned by PUF Ventures Inc. (CSE: PUF), MYM Nutraceuticals Inc. (CSE: MYM), Chrome Holdings of Australia and private investors. It has submitted applications and plans with Australia's Office of Drug Control to build a 1.2 million square-foot greenhouse facility with cannabis production space and a medical research center in the Northern Rivers Region of New South Wales, Australia. Solaris' corporate mission is to deliver environmentally friendly, sun grown medicinal grade cannabis and to develop medicines and treatments for pain management and other medical conditions. The company's focus is on innovations that promote, support and deliver improvements in the quality, consistency and cost of medicines to our clients. For more information, visit www.solarisnutraceuticals.com.
About PUF Ventures Inc.
PUF Ventures Inc. is a growth oriented and diversified company focused on the international cannabis industry. It has ownership in several cannabis companies: AAA Heidelberg, Solaris Nutraceuticals Pty Ltd., and Natures Hemp Corp., and is actively pursuing other opportunities within the industry. PUF has an option to purchase 100% of AAA Heidelberg Inc., a private Ontario company and advanced applicant for an ACMPR license. Solaris Nutraceuticals is building the largest medical cannabis greenhouse in the Southern Hemisphere. For more information please visit: www.puf.ca.
ON BEHALF OF THE BOARD OF DIRECTORS
Derek Ivany
President & CEO
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer's future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.
Future Farm Receives Three Industrial Hemp Licenses For 2018
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/15/Future-Farm-Receives-Three-Industrial-Hemp-Licenses-For-2018
VANCOUVER , British Columbia, February 15, 2018 /PRNewswire/ -- Future Farm Technologies Inc. (the "Company" or "Future Farm") (CSE:FFT) (OTC:FFRMF) is pleased to announce that its subsidiary, Future Farm Maine, LLC, has received three licenses from the State of Maine for the cultivation of industrial hemp in 2018. Future Farm Maine received one license for each of its Amity and Hersey farms, as well as one for the Belfast processing facility.
Mr. Bill Gildea, CEO of Future Farm, comments, "We are thrilled to have received these three licenses to operate our industrial hemp business in Maine and are excited to build our high value, vertically integrated industrial hemp farm and CBD oil production facility in 2018."
As recently announced, the Company signed a lease agreement for an initial 12,960 sq. ft. of space in a 60,000 sq. ft. building, with an option to expand or buy the building. Future Farm Maine will use the Belfast building to germinate 250,000 hemp seeds over the next few months, which then will be planted to meet the summer growing season at the Amity and Hersey farms. With over 100 organic certified acres ready to plant and an additional 1,000 acres available for expansion, Future Farm Maine is poised to be the largest hemp farm in the North East.
Future Farm Maine plans to use feminized seeds of the highest quality, CBD strains in the industry that test in compliance of hemp laws of having .03% THC or less while averaging 15% CBD. The hemp seeds will also be germinated under the Company's LED grow lights, which will save on electricity costs and further leverage its in-house technology. Once harvested, the hemp will be dried and further refined using Future Farm's high output oil processing equipment creating both CBD oil and high value isolate for making edibles, creams and lotions.
Future Farm is also pleased to announce that it has engaged Mr. Zachary Lapan to oversee the Company's Maine cultivation and processing operations. Mr. Lapan has worked closely with Derek Ross providing operational oversight for ten years. Mr. Lapan has deep community and agricultural ties to Maine, and is excited to provide operational expertise in Future Farm Maine's portfolio of projects.
"Growing hemp in northern Maine requires local, agricultural and climate expertise," comments Derek Ross, President of Cannatech and Future Farm's joint venture partner in Maine. "Mr. Lapan is a successful, seasoned hemp farmer and I'm excited that he has joined the team."
Comments Mr. Lapan, "It is time to get to work! This is going to be fun and I'm excited to be on the forefront of the hemp industry here in Maine. We have an aggressive schedule to develop our propagation facility and we will hire the best and most talented local resources to get the job done."
The market for CBD is poised for expansion due in part to the FDA's acceptance of a New Drug Application submitted by GW Pharmaceuticals plc for Epidiolex®, a drug containing CBD. Three Goldman Sachs analysts projected 2025 worldwide sales of US$2.2 billion for Epidiolex®, with more than half (56 percent) of the sales coming from off-label use. Sales of CBD in the United States across the hemp-derived, marijuana-derived and pharmaceutical industries is projected to reach $1.1 billion by 2020, according to Hemp Business Journal.
The Company also confirms that the Board of Directors has approved the cancellation of 3,875,000 incentive stock options currently exercisable at $1.24CDN.
On behalf of the Board,
Future FarmTechnologies Inc.
William Gildea, CEO & Chairman
About Future Farm
Future Farm Technologies Inc. is a Canadian company with projects throughout North America including California, Florida and Maryland. The Company's business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants, with a focus on cannabis. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generates yields up to 10 times greater per square foot of land. The contained system provides many other benefits including 90% less water, fertilizer and land used, less travel costs, seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability. The Company also utilizes a leading cannabis oil extraction technology, which enables the Company to process 20lbs/hour of cannabis plant to yield approximately 908 grams/hour of oil.
The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com, which caters to B2B customers, is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com, which caters to both large and small agriculture green houses and controlled cultivation centers.
The Company recently acquired the exclusive right to use a patented, augmented reality (AR) technology in the cannabis industry. As described in more detail above, the Company has decided to spin this asset off to its shareholders.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Nutritional High Announces Oregon & Washington Project Updates
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/15/Nutritional-High-Announces-Oregon-Washington-Project-Updates
TORONTO, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Nutritional High International Inc. (the "Company" or "Nutritional High") (CSE:EAT) (OTC:SPLIF) (FRANKFURT:2NU) is pleased to announce an update regarding the build-out at its facility in the City of La Pine, Oregon and provide an update regarding the Company’s product rollout in Washington State. The Company also wishes to announce the entry into an addendum to Purple Haze License Agreement.
Oregon Project Update
In Oregon, the Company engaged a contractor in late fall of 2017 who has been working to complete the remodeling of the La Pine facility. To date, the contractor has completed plumbing, wall modifications and floor drains, and is in the process of completing the electrical work and security surveillance installation. The Company had minor construction delays due to weather, but is on track to complete the build-out in calendar Q1 of 2018 and schedule the necessary inspections.
After completing the construction and equipment installation, the facility will be inspected by the Oregon Department of Agriculture, and Oregon Liquor Control Commission ("OLCC"), upon successful completion of which the recreational processing license ("License") from the State will be granted. The final steps in the local permitting process include the inspection by the Building Department of Deschutes County and certain departments of the City of La Pine, including the fire Chief, Planning Department and the City Manager.
The Company has completed the design of FLI-branded packaging that is compliant with the OLCC regulations in order to accelerate the launch of its products shortly after licensing is granted. The Company is also in the process of interviewing potential candidates for management, extraction specialist and sales roles for its facility.
Washington Project Update
As announced in Company's press release dated October 30, 2017, Nutritional High has entered into an agreement to lease the real estate property in Bellingham, WA ("Bellingham Property"). The Bellingham Property has been sub-leased to Mt. Baker Greeneries, LLC ("Mt. Baker Greeneries") which holds a Tier 2 Producer and Processor Licenses issued by the Washington State Liquor and Cannabis Board ("WSLCB").
Mt. Baker Greeneries has been focused on renovating and upgrading its facility to enable Mt. Baker Greeneries to implement Nutritional High’s SOPs, know-how and infusion techniques. These upgrades and improvements will allow Mt. Baker Greeneries to manufacture high quality distillate cannabis oil that would be used to fill FLI-branded vape cartridges, including a new Live Resin line. Nutritional High and Mt. Baker Greeneries have also identified the equipment upgrades that are required for the Bellingham Property to implement the necessary extraction and manufacturing techniques.
Jim Frazier, CEO of Nutritional High commented: "We're excited to move another step closer to establishing operations in the Pacific North West. The Oregon and Washington legal cannabis markets represent a lucrative opportunity for premium-focused concentrate and edibles manufacturers. Nutritional High is planning to make its debut in these markets by introducing its flagship FLI vape cartridges, followed by other products that we have developed or licensed from branding partners."
Addendum to Purple Haze License Agreement
The Company has entered into an addendum (the “Addendum”) to the Company’s license agreement (“License Agreement”) with Purple Haze Properties LLC (“PHP”) effective January 25, 2018. Pursuant to the Addendum, the Company has agreed to satisfy its 2017 License Agreement obligations to PHP and to meet its 2018 License Agreement obligation via issuance of 750,000 common shares in the capital of the Company (“Common Shares”) to PHP. The Addendum also includes two one-year options to extend the License Agreement at the Company’s sole discretion and provides that a portion of the stock issuances and all the owed monetary royalties shall be placed in an escrow account for contingencies.
About Nutritional High International Inc.
Nutritional High is focused on developing, manufacturing and distributing premium and consistently dosed products in the cannabis-infused products industry, including edibles and oil extracts for nutritional, medical and adult recreational use. The Company works exclusively through licensed facilities in jurisdictions where such activity is permitted and regulated by state law.
For updates on the Company's activities and highlights of the Company's press releases and other media coverage, please follow Nutritional High on Facebook, Twitter, Instagram and Google+ or visit www.nutritionalhigh.com.
For further information, please contact:
David Posner, Chairman of the Board
Nutritional High International Inc.
647-985-6727
Email: dposner@nutritionalhigh.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR OTC MARKETS GROUP INC., NOR THEIR REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe and to the satisfaction of the relevant regulators, completing the acquisition of the applicable real estate and raising sufficient financing to complete the Company's business strategy. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulation S under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.
Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
CannaRoyalty Enters Partnership With Northern California Craft Cultivator
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/15/CannaRoyalty-Enters-into-Strategic-Partnership-with-Leading-Premium-Craft-Cannabis-Cultivator-FloraCal%25C2%25AE-Farms-to-Develop-and-Sell-Branded-Cannabis-Products
OTTAWA, Feb. 15, 2018 /PRNewswire/ - CannaRoyalty Corp. (CSE:CRZ) (OTC:CNNRF) ("CannaRoyalty" or the "Company"), an active investor and operator in the legal cannabis industry, announced today that it has signed a binding Letter of Intent (the "LOI") with FloraCal® Farms ("FloraCal") to enter into a strategic partnership regarding craft premium cannabis flower production, branding and sales, and other strategic initiatives (the "Strategic Partnership"). The LOI also contemplates the receipt by CannaRoyalty of the exclusive global rights to license FloraCal's full Intellectual Property ("IP") portfolio, inclusive of brand, outside of California.
FloraCal is a 100% family owned and operated cultivator in Northern California that handcrafts, brands and packages small batches of ultra-premium cannabis flower, with an average selling price of over US$17 per gram. FloraCal's products are currently available in over 210 dispensaries in California through CannaRoyalty investee River Distribution ("River"). The Company and FloraCal will jointly execute a purpose-built expansion into CannaRoyalty's existing 20,000 square foot facility in Sonoma County, which is strategically adjacent to both River and FloraCal's current manufacturing and cultivation facilities.
"This Strategic Partnership fills an important adjacency in our value-added downstream product portfolio and moves the Company closer to achieving its 2018 objectives in California," said Marc Lustig, CEO of CannaRoyalty. "We have assessed several cultivation facilities and flower brands across North America over the past three years, and FloraCal's facility and products were an outlier in terms of product presentation, brand recognition and overall quality. FloraCal's success has demonstrated that at the high-end of the cannabis flower market, top-quality branded products can consistently obtain premium pricing and capture a meaningful portion of downstream profits. Given that combined sales of flower and pre-roll products comprised approximately 52%1 of all 2017 cannabis sales in California, these categories represent an important portion of any premium, full-shelf cannabis product portfolio. Furthermore, we see strong potential to leverage FloraCal's IP in other markets, such as Canada, as they develop."
"We have built a solid reputation and consumer following in California for our suite of small-batch cannabis flower products, which have some of the highest tested THC and cannabinoid percentages in the market," added Drew Duval, CEO of FloraCal. "CannaRoyalty's expertise and reputation in California make them the ideal partner to work with as we continue to expand our production and distribution footprint over the coming months, while developing new premium cannabis flower products and strains."
As previously disclosed, CannaRoyalty has leased space in River's 20,000 square foot facility in Sonoma County. The leased space is located in the same building as FloraCal's existing 43,000 square foot cultivation and manufacturing facility. CannaRoyalty intends to leverage the existing planning and design work that has been completed by FloraCal for its own cultivation facility.
Sonoma County is one of the most opportunistic counties in California in seeing the economic benefits of cannabis production and is at the forefront in implementing innovative approaches to regulation. It is among the first to set up permitting and tax programs. Sonoma County is at the bottom of a 3-county area called the Emerald Triangle, which has a rich history of leading legal cultivation and production for the medical cannabis industry.
1 2017 Brightfield Group
About Floracal® Farms
FloraCal® Farms is located in Sonoma County. FloraCal's® team of master cultivators strive to create beautiful consistent cannabis products with a smooth finish, believing it all starts from the seed and are dedicated to hand selecting the finest genetics. Their natural biodynamic farming techniques allow FloraCal® to consistently produce top shelf flowers at the highest quality for its customers.
FloraCal possesses a unique and rare genetics collection, currently encompassing seven ultra-high-quality cannabis flowers along with rosin and packaged pre-rolls. FloraCal uses proprietary, highly scalable cultivation techniques and related intellectual property that enable the company to achieve consistent, ultra-premium products. Some product highlights include:
THC between 28-32% for commercial production (have been tested up to 33% THC)
Very successful line of premium pre-rolls distributed through River
First cultivation license issued in Sonoma county for cultivation in 2018
Also licensed for manufacturing and extraction
15,000 square feet currently, with additional expansion room for a total of 43,000 square feet
Maximum production for fully expanded facility is 3,700kg annually
About CannaRoyalty
CannaRoyalty is an active investor and operator in the legal cannabis industry. Our focus is building and supporting a diversified portfolio of growth-ready assets in high-value segments of the cannabis sector, including research, consumer brands, devices and intellectual property. Our management team combines a hands-on understanding of the cannabis industry with seasoned financial know-how, assembling a platform of holdings via royalty agreements, equity interests, secured convertible debt, licensing agreements and its own branded portfolio. CannaRoyalty's shares trade on the Canadian Stock Exchange (CSE) under the symbol CRZ and internationally on the OTCQX under the symbol CNNRF.
Forward Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CannaRoyalty's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward- looking statements.
Forward-looking statements may include, without limitation, statements regarding the Company's expectations with respect to pursuing new opportunities and future growth for Trichome and other statements of fact.
Although CannaRoyalty has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: competition from banks and other lenders; movements and long term trends in interest rates; the ability of management to select companies that will increase in value and to compete for desirable transactions; the ability to source desirable transactions; dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history; changes in laws; limited operating history; reliance on management; requirements for additional financing; and regulatory or political change.
There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.
Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CannaRoyalty disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CannaRoyalty does not assume any liability for disclosure relating to any other company mentioned herein.
Isodiol to Acquire 100% Of Canadian National Pharma Group Inc.
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/15/Isodiol-to-Acquire-100-Of-Canadian-National-Pharma-Group-Inc
VANCOUVER, British Columbia, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has entered into a Definitive Agreement to acquire 100% of Canadian National Pharma Group Inc. (CN Pharma), a pharmaceutical manufacturing company. Isodiol previously announced on Dec. 6th, 2017 the agreement to acquire an initial stake representing 25% equity of CN Pharma. The company is now pleased to purchase the remaining 75% equity and is excited to establish CN Pharma as a wholly owned subsidiary.
Once approved by Health Canada, CN Pharma will be licensed to process and manufacture controlled substances, handle all cannabis and hemp derivatives, import and export oils and isolates, prepare various formulation and mixtures, participate in research or testing activities, and conduct new product and drug development.
“This is a strategic acquisition for Isodiol, and we intend to expand our capacity in Canada in a significant way,” said Marcos Agramont, CEO of Isodiol. “With this new and up and coming facility, Isodiol will be able to refine and isolate the CBD molecule to a pharmaceutical-grade purity of 99.5% + as well other Cannabinoid derivatives. As a certified Licensed Dealer, Isodiol will continue to establish strategic partnerships and product licensing agreements with Licensed Producers, and expand our product sales into major retailers across Canada that are looking to enter the fast-emerging CBD market.”
Being uniquely positioned with a global footprint and strategy, Isodiol is actively establishing the required infrastructure and partnerships to commercialize it cannabinoid therapeutics, innovating drug formulas and delivery technologies, as well as establishing the best manufacturing practices.
“The CN Pharma structure will provide Isodiol with a unique opportunity to import optimal cannabis and hemp ingredients from various global centers in to Canada and then process and manufacture to the highest quality pharmaceutical standards. The license will also position Isodiol to export its pharmaceutical products globally from Canada”, said Marcus Dahl, President of CN Pharma.
Per the agreement, Isodiol will issue a total of $6,000,000 CDN in stock for 100% of the acquisition, based on the closing price of February 14, 2018, subject to escrow guidelines, per the CSE.
For more information on Isodiol, please visit www.isodiol.com
For more information on please visit www.canadiannationalpharmagroup.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
604-409-4409
marcos@isodiol.com
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.
Emerald Health Granted European Orphan Designation for EHP-101
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/15/Emerald-Health-Granted-European-Orphan-Designation-for-EHP-101
SAN DIEGO, CA / ACCESSWIRE / February 15, 2018 / Emerald Health Pharmaceuticals Inc. ("EHP"), which is developing medicines based on cannabinoid science, today announced that the European Medicines Agency ("EMA") has granted Orphan Designation for EHP's lead molecule, EHP-101, for the treatment of systemic scleroderma, also called systemic sclerosis ("scleroderma"). This chronic autoimmune disease causes severe fibrosis of the skin and internal organs and is associated with significant morbidity and mortality.
Orphan Designation provides potential incentives from the EU to develop a medicine for a rare disease, including protocol assistance, reduced fees, funding from the European Commission for clinical trials, and protection from competition once the medicine is placed on the market, including ten years of market exclusivity.
"The EMA's granting of Orphan Designation for EHP-101 for scleroderma adds additional value when combined with the US FDA's recent granting to us of Orphan Drug Designation, giving us further incentive and opportunity to advance a possible solution for patients suffering from this terrible disease that has no cure," said Jim DeMesa, MD, CEO of EHP. "Since we are developing EHP-101 for multiple sclerosis as well as scleroderma, we now have indications for small patient populations at the same time that we plan our clinical studies for more prevalent diseases."
EHP's lead product candidate, EHP-101, is a patented new chemical entity derived from cannabidiol (CBD) that is being developed for the treatment of multiple sclerosis and scleroderma. The company plans to initiate a Phase 1 human clinical study in 2018 and potentially initiate Phase 2 studies for multiple sclerosis and scleroderma in 2019. EHP's second drug candidate, EHP-102, a cannabigerol (CBG) derivative, is being developed for Parkinson's disease and Huntington's disease.
The European Commission's European Medicines Agency ("EMA") plays a central role in facilitating the development and authorization of medicines for rare diseases, or "orphan medicines." To qualify for orphan designation in Europe, a medicine must be intended for the treatment, prevention or diagnosis of a disease that is life-threatening or chronically debilitating; the prevalence of the condition in the EU must not be more than 5 in 10,000 or it must be unlikely that marketing of the medicine would generate sufficient returns to justify the investment needed for its development; and no satisfactory method of diagnosis, prevention or treatment of the condition concerned can be authorized or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.
About EHP-101
EHP-101 is a patented new chemical entity derived from cannabidiol (CBD), which has been modified to enhance the therapeutic benefits of CBD by being a dual PPAR? and CB2 agonist that also affects the hypoxia inducible factor (HIF) pathway. There is evidence that these validated receptors may be beneficial in preventing neuroinflammation and demyelination in the central nervous system, and fibrogenesis in the periphery. Emerald is developing this drug candidate for multiple sclerosis and scleroderma.
About Systemic Scleroderma
Systemic scleroderma (or systemic sclerosis) is a rare and chronic autoimmune disease causing fibrosis of skin and internal organs and can also affect blood vessels, muscles, and joints. The tissues of involved organs become hard and fibrous, causing them to function less efficiently. While the symptoms of systemic scleroderma vary for each person, it can be life-threatening, depending on which parts of the body are affected and the extent of disease. The disease is more common in adults. Currently, there are no approved treatments specific to systemic scleroderma, and the current therapies for scleroderma are limited in efficacy and may contain toxicities. New treatments and early diagnosis will be critical to help reduce the symptoms of systemic scleroderma and prevent further damage to the body.1
About Emerald Health Pharmaceuticals Inc.
Emerald Health Pharmaceuticals is developing product candidates derived from cannabinoids for the treatment of inflammatory, autoimmune, metabolic, neurodegenerative, and fibrotic diseases. The company has two families of new chemical entities, based on CBD and CBG, that it has modified through rational drug design to affect validated receptors pertinent to targeted diseases. Its first drug candidate, EHP-101, is focused on treating multiple sclerosis and scleroderma. Its second, EHP-102, is focused on treating Huntington's disease and Parkinson's disease. The company is advancing preclinical development with the intent to launch a Phase 1 clinical study in 2018.
For more information, visit www.emeraldpharma.life or contact: info@emeraldpharma.life.
To the extent statements contained in this news release are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered "forward-looking statements," as described in the private securities litigation reform act of 1995, that reflect management's current beliefs and expectations. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "hope," "hypothesis," "intend," "may," "plan," "potential," "predict," "project," "should," "strategy," "will," "would," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in these presentations include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) the anticipated timing of clinical data availability; (v) our ability to meet our milestones; and (vi) our expectations regarding our ability to obtain and maintain intellectual property protection. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA.
Canopy is one of 6 Companies Chosen to Supply Cannabis to Quebec!
So apparently Canopy is one of the 6 companies chosen to supply cannabis for quebec
The others are here: https://www.dailymarijuanaobserver.com/single-post/2018/02/14/6-Companies-Chosen-to-Supply-Cannabis-to-Quebec?utm_campaign=48a392db4d-EMAIL_CAMPAIGN_2018_02_14&utm_medium=email&utm_source=D.M.O.%2BNewsletter&utm_term=0_75e1ee9d7e-48a392db4d-71132567
Its odd that Canopy didnt get the largest deal! Looks like it was hydropethecary oddly enough. The smallest on the list
HempAmericana Executes Contract To Acquire Local Farm for Seed Production
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/14/HMPQ-HempAmericana-Executes-Contract-To-Acquire-Local-Farm-for-Seed-Production?utm_campaign=48a392db4d-EMAIL_CAMPAIGN_2018_02_14&utm_medium=email&utm_source=D.M.O.%2BNewsletter&utm_term=0_75e1ee9d7e-48a392db4d-71132567
NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- HempAmericana, Inc. (OTC:HMPQ) (“HempAmericana” or the “Company”) is excited to announce the potential acquisition of a ten acres farm in Maine. The Company plans to use the facility for genetic testing and cultivation of super high-potency seeds as a supply input for its CBD Oil extraction and processing facility in nearby Augusta, Maine
Seven acres of the 10 acres are encircled by a deer fence and features a full drainage system and multiple spring-fed wells for irrigation. The property has been cleared and is farming-ready at present. The Company plans to construct multiple greenhouses on the farm as well.
As far as productive capacity, management believes the farm can support as many as 84,000 hemp plants. The Company plans to employ special strains known for generating super-concentrated CBD yields, and to genetically cross them with other strains to maximize the potency of CBD Oil being produced at its primary extraction and processing facility.
HempAmericana CEO, Salvador Rosillo, commented, “One of the benefits of being in a strong financial position before switching on a new major facility is the ability to make strategic investments in key inputs to date the company has zero Bank debt. Owning our own seed cultivation and research facility will not only grant the Company strength at the negotiating table but will also allow us to invest in truly putting the highest quality product out there while acting as a dampening force to counter price gouging in the regional hemp seed market.”
This step toward verticalization may be followed by additional steps of a similar nature in 2018 as the Company continues to lay down a foundation capable of supporting an industry-dominant position as a high-capacity producer in the $2.1B CBD Oil space.
Mr. Rosillo continued, “We aren’t just looking to become the biggest high-potency CBD Oil operation east of the Mississippi... We are setting the stage to become the go-to force at all levels of this business.”
About HempAmericana, Inc.
HempAmericana is currently in the rolling paper and CBD oil business using the brand name Weed Got Oil. Search Rolling Thunders hemp papers on YouTube for a product demonstration of the Company's papers. The company owns an extraction machine and now plans to become a leader in the CBD oil market by establishing three laboratories for the extraction and research of the oils contained in the hemp plant. HempAmericana also researches, develops and sells products made of industrial hemp. See more at http://www.HempAmericana.net.
Safe Harbor Provision Cautionary statement for purposes of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995: Information in this news release contains forward-looking statements that involve risks, uncertainties and assumptions. If such risks or uncertainties materialize or such assumptions prove incorrect, the results of the Company and its consolidated subsidiaries could differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Risks, uncertainties and assumptions include the execution and performance of contracts by the Company and its customers, suppliers and partners. Please also review Hemp Americana annual and quarterly financials for a more complete discussion of risk factors. The Company disclaims any obligation to update or revise statements contained in this news release based on new information or otherwise. This communication shall not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state in which such solicitation or sale would be unlawful prior to registration or qualification of these securities under the laws of any such state.
EVIO Inc. Reports Q1 2018 Financial and Operating Results
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/14/EVIO-Inc-Reports-Q1-2018-Results
BEND, Ore., Feb. 14, 2018 (GLOBE NEWSWIRE) -- via NetworkWire - EVIO, Inc. (OTC:EVIO), a leading provider of quality control testing and advisory services to the regulated cannabis industry, announces financial and operating results for the quarter ended December 31, 2017.
First Quarter Fiscal 2018 Financial Summary
First quarter revenue was $946,865, up 41.6% from first quarter last year.
First quarter gross profit was $210,602, up 168% from first quarter last year.
First quarter testing revenue was $887,349, up 56.1% from first quarter last year.
First quarter cash position has increased to $221,820.
Executive Commentary
“We are pleased with our first quarter results, especially with the year over year increase in activity in Oregon. The company is continuing to focus on laying a strong foundation to build upon,” stated William Waldrop, EVIO’s chairman and Chief Executive Officer. “With recent accreditation of our pesticide equipment in Oregon, we are beginning to feel the positive impact including a significant improvement in our gross margin going into our second quarter.”
Mr. Waldrop continued, “With our recent private placement of $5.973 million, EVIO is now focused on rapidly building out the California marketplace to meet the growing demand for state mandated compliance testing. We have consolidated our Yuba City operations into our new Northern California laboratory in Berkeley to improve proficiency and economics. The Company is moving forward with the build-out of a new lab in Costa Mesa, CA as well as finalizing discussions for other regional service centers.”
About EVIO, Inc.
EVIO, Inc. is a life sciences company focused on analyzing cannabis as a means for improving quality of life. The Company provides analytical testing services, advisory services and performs product research in its accredited laboratory testing facilities. The Company’s EVIO Labs division, operating coast-to-coast, provides state-mandated ancillary services to ensure the safety and quality of the nation's cannabis supply.
For more information, visit www.eviolabs.com
Safe Harbor Statement
Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at www.sec.gov or www.eviolabs.com
GrowGeneration Purchases Assets of Groco Supply
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/14/GrowGeneration-Purchases-Assets-of-Groco-Supply
Denver,CO., Feb. 14, 2018 (GLOBE NEWSWIRE) -- GrowGeneration Corp. (OTC:GRWG), GrowGeneration (“GrowGen” or the “Company”), one of the largest specialty retail hydroponic and organic gardening stores, with currently 17 locations serving both commercial and home growers, today announced that it has purchased certain assets of Groco Supply located in Bellevue, WA. The assets include both inventory and customer accounts equaling up to $1.0M in new business for GrowGeneration Washington.
GrowGen CEO Comments
Commenting on GrowGen’s asset purchase of Groco Supply, Darren Lampert, Co-Founder and CEO, said, " The purchase of the assets of Groco demonstrates GrowGen’s strategy to consolidate new customers and revenue from hydroponic stores who are looking to align with a national company that has economies of scale. GrowGen is identifying these types of opportunities around the country that are accretive to revenue and income.”
About GrowGeneration Corp.:
GrowGeneration Corp. (“GrowGen”) owns and operates specialty retail hydroponic and organic gardening stores. Currently, GrowGen has 17 stores, which includes 9 locations in Colorado, 4 locations in California, 2 locations in Las Vegas, 1 location in Rhode Island and 1 location in Washington. GrowGen carries and sells thousands of products, including organic nutrients and soils, advanced lighting technology and state of the art hydroponic equipment to be used indoors and outdoors by commercial and home growers. Our mission is to own and operate GrowGeneration branded stores in all the major legalized cannabis states. Management estimates that roughly 1,000 hydroponic stores are in operation in the U.S. By 2020 the market is estimated to reach over $23 billion with a compound annual growth rate of 32%.
Forward Looking Statements:
This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws. While these forward-looking statements represent our current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this release. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as "look forward," "believe," "continue," "building," or variations of such words and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by us herein are often discussed in filings we make with the United States Securities and Exchange Commission, available at: www.sec.gov, and on our website, at: www.growgeneration.com.
MedReleaf Reports Third Quarter Fiscal 2018 Results
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/13/MedReleaf-Reports-Third-Quarter-Fiscal-2018-Results
MARKHAM, ON, Feb. 13, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF)(OTC:MEDFF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced financial and operating results for the third quarter fiscal 2018 ending December 31, 2017. All amounts expressed are in Canadian dollars unless otherwise noted.
"In the third quarter, we set new records for total sales and grams sold demonstrating the strength of our underlying business while we continue to make investments in preparation for the recreational market and for international expansion," said Neil Closner, CEO of MedReleaf. "These investments are starting to bear fruit and we now have boots on the ground in six different countries working on various initiatives – both for cultivation and export. We also launched our first adult recreational-use brand, San Rafael '71, which is getting good reception from the various Provincial purchase authorities. With a strong balance sheet bolstered by $192.5 million in equity capital raised since last December, we have a clear opportunity to establish MedReleaf as a global leader in the cannabis industry."
REST OF RELEASE: https://www.dailymarijuanaobserver.com/single-post/2018/02/13/MedReleaf-Reports-Third-Quarter-Fiscal-2018-Results
Aphria Announces Closing of Broken Coast Cannabis Acquisition
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/13/Aphria-Announces-Closing-of-Broken-Coast-Cannabis-acquisition
LEAMINGTON, ON, Feb. 13, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX:APH) (OTC:APHQF) today announced that it has closed the previously announced acquisition (the "Transaction") of Broken Coast Cannabis Inc. ("Broken Coast"), a leading premium cannabis producer located in British Columbia, acquiring 99.86% of all of the issued and outstanding Class A common shares.
The closing was effected pursuant to the terms of a definitive share purchase agreement (the "SPA") dated the date hereof by and among the Company and the vendors party thereto (collectively, the "Vendors"). Pursuant to the SPA, the Company has acquired the Class A common shares held by the Vendors for an aggregate purchase price of approximately CAN$217 million, subject to customary adjustments. The purchase price has been satisfied by Aphria issuing to the Vendors today an aggregate of 14,373,675 common shares in the capital of the Company.
"We're excited to complete this transaction and add one of Canada's most sought after premium brands to our portfolio," said Vic Neufeld, Chief Executive Officer of Aphria. "Broken Coast brings award-winning production of small-batch, premium-quality "B.C. bud" and a shared focus on production costs and profitability. When combined with Aphria's experience in scaling and supply chain management, this acquisition firmly establishes our position as a Canadian leader in premium indoor cannabis production."
Broken Coast operates a fully licensed, purpose-built, indoor cannabis production facility on Vancouver Island. As part of the Transaction, Aphria approved the immediate commencement of Broken Coast's Phase IV expansion (the "Expansion"), which will increase the facility's annual capacity from 4,500 kg per year to 10,500 kg per year. The Expansion is anticipated to be completed by late summer 2018, with first product sale occurring in early 2019.
The Expansion will raise Aphria's forecasted annual production to 230,000 kg, anticipated by February 2019, while also providing Aphria with geographic diversification, a cross-Canada distribution platform, and access to over 40,000 medical patients.
For further details on the Transaction, see the Company's press release dated January 15, 2018, available on SEDAR at www.sedar.com.
We Have a Good Thing Growing.
About Aphria
Aphria Inc., one of Canada's lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to internal expectations, estimated margins, expectations relating to the Expansion and the anticipated benefits resulting therefrom, expectations for future growing capacity and costs, and expectations with respect to future production costs. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Maricann Group Inc. Welcomes VP of Sales and Marketing
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/13/Maricann-Group-Inc-Welcomes-VP-of-Sales-and-Marketing
Toronto, ON -- Feb. 13, 2018 -- / D.M.O. Newswire / -- Maricann Group Inc. (CSE:MARI) (FRANKFURT: 75M) (“Maricann” or “The Company”), is pleased to welcome Geoff Kosar to the team. Geoff is joining Maricann in the role of Vice President, Sales & Marketing and will provide leadership to all commercial activities with a focus on the recreational aspect of the business – if, and when legalized.
Geoff brings with him a wealth of experience. Most recently he was Head of Marketing at one of the largest spirits companies in Canada. Geoff spent 8 years in that role and during that time provided guidance to brand development and market penetration strategies for many leading spirit & beer brands.
Geoff has demonstrated a record of success as acting Business Unit Director and Category Manager for wines with the Liquor Control Board of Ontario (LCBO). Strong leadership in brand strategy development, digital marketing, and relationship management are key strengths that Geoff brings to Maricann.
“Geoff’s demonstrated leadership at one of Canada’s largest spirits companies, specifically in brand development and line extensions within product categories, will ensure Maricann is well positioned in the Canadian recreational market.” - Ben Ward, Maricann CEO
“I look forward to build on Maricann’s success, to establish Maricann as a leader in the recreational market” - Geoff Kosar, Maricann VP Sales & Marketing
About Maricann Group Inc.
Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada, and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) build out, capable of producing 95,000 kg of dry cannabis flower per year to support existing and future patient growth.
For more information about Maricann, please visit our website at www.maricann.com.
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
FORWARD LOOKING INFORMATION
Certain statements in this press release contain forward-looking statements, including with respect to the Company’s positioning in the recreational cannabis market and future production capacity, which can be identified by the use of forward-looking terminology such as “believes”, “expects”, “may”, “desires”, “will”, “should”, “projects”, “estimates”, “contemplates”, “anticipates”, “intends”, or any negative such as “does not believe” or other variations thereof or comparable terminology. No assurance can be given that potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein, that could cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect the view of the Company with respect to future events, and are based on information currently available to the Company and on assumptions, which it considers reasonable. Management cautions readers that the assumptions relative to the future events, several of which are beyond Management’s control, could prove to be incorrect, given that they are subject to certain risk and uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to differ from current expectations include, among other things: uncertainties with respect to legalization of recreational cannabis; risks inherent to expansion project; fluctuations in operating results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees; fluctuations in cash flow; increased levels of outstanding debt and obligations under a capital lease; expectations regarding market demand for particular products and the dependence on new product development; the impact of market change; and the impact of price and product competition, as well as other risks discussed in its latest annual information form and other disclosure documents of the Company available at www.sedar.com. Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking information.
Canopy Growth Corporation Issues Common Shares Worth $5 Million
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/13/Canopy-Growth-Corporation-Issues-Common-Shares
SMITHS FALLS, ON, Feb. 13, 2018 /CNW/ - Canopy Growth Corporation (TSX:WEED) (OTC:TWMJF) ("Canopy Growth" or the "Company") is pleased to announce that it has acquired certain intellectual property assets and know-how for total proceeds of $5,325,250 of which $3,132,500 was paid on closing by issuing 117,253 common shares of the Company based on the 5 day VWAP of $26.7157. The remaining consideration of $2,192,750 will be paid over a series of milestones in common shares of the Company at the 5-day VWAP when each milestone is achieved.
About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.
Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Organa Brands, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands. Canopy Growth operates seven cannabis production sites with over 665,000 square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The Company has operations in seven countries across four continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and through its partly owned subsidiary, Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth.
Here's to Future Growth.
Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could","would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, Tweed Inc., Tweed Farms Inc. or Bedrocan Canada Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection. The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corp. does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.
Kush Bottles and Merida Capital Announce $6 Million Investment
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/13/Kush-Bottles-and-Merida-Capital-Partners-Announce-Strategic-Partnership-and-6-Million-Investment
SANTA ANA, Calif., Feb. 13, 2018 /PRNewswire/ -- Kush Bottles, Inc. (OTC:KSHB) ("Kush Bottles" or the "Company"), a leading provider of packaging, supplies, vaporizers, accessories and branding solutions for the regulated cannabis industry, today announced that it has entered into a strategic partnership with a leading cannabis ancillary fund, Merida Capital Partners ("Merida"), and has received a $6 million equity investment from Merida to accelerate its near and long-term growth strategy. Kush Bottles plans to use the proceeds to expand its product portfolio, build new distribution channels and penetrate new legalized markets.
The strategic partnership will focus on building Kush Bottles' East Coast distribution platform, and expanding the Company's footprint in medical and adult-use markets on the East Coast, where Merida has a strong presence. This will also create the opportunity for Kush Bottles, with Merida's assistance, to develop and execute its acquisition pipeline.
Nicholas Kovacevich, Chairman and CEO of Kush Bottles, commented: "The Merida team's deep understanding of the unique dynamics of the cannabis industry, strong industry networks and willingness to finance our growth will be invaluable as we exploit new opportunities and enter new markets. We plan to use this capital investment to expand our range of proprietary products to meet the needs of the industry, advance our M&A strategy to take advantage of consolidation in the industry and grow market share."
Merida's Managing Partner, Mitchell Baruchowitz, commented: "Since we first started discussing a partnership and investment in Kush Bottles nearly seven months ago, we have been deeply impressed by the vision of Nick and his team and the progress they have made strategically positioning Kush Bottles as much more than simply a packaging company. Kush Bottles' acquisitions and in-house development efforts have established the Company as a critical link in the supply chain for more than 5,000 cannabis growers, extractors, manufacturers and retailers. The Merida team could not be more excited to put significant resources to work to build on this foundation to expand Kush Bottles' leading position."
To be added to the distribution list, please email ir@kushbottles.com with "Kush" in the subject line.
About Kush Bottles
Kush Bottles, Inc. (OTCQB: KSHB) is a dynamic sales platform that provides unique products and services for both businesses and consumers in the cannabis industry. Founded in 2010 as a packaging and supplies company for dispensaries and growers, Kush Bottles has sold more than 100 million units and now regularly services more than 5,000 legally operated medical and adult-use dispensaries, growers, and producers across North America, South America, and Europe. The Company has facilities in the three largest U.S. cannabis markets and a local sales presence in every major U.S. cannabis market.
Kush Bottles aims to be the gold standard for responsible and compliant products and services in the cannabis industry. Kush Bottles has no direct involvement with the cannabis plant or any products that contain THC.
The Company has been featured in media nationwide, including CNBC, Los Angeles Times, TheStreet.com, Entrepreneur, and business magazine Inc.
For more information, visit www.kushbottles.com or call (888)-920-5874.
About Merida Capital Partners
Merida Capital Partners is a private equity fund targeting fundamental growth drivers which accelerate the rapid development of the cannabis industry. Our investment emphasis focuses on cultivation technologies and products and services associated with the evolution of cannabis as an agricultural product, a natural plant-based medicine, a constituent in pharmaceutical formulations, and a recreational consumer product. For more information, please visit www.meridacap.com.
Forward-Looking Statements
This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws. While these forward-looking statements represent the Company's current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect the opinions of the Company's management only as of the date of this release. Please keep in mind that the Company is not obligating itself to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as: "potential," "look forward," "believe," "dedicated," "building," or variations of such words and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by the Company herein are often discussed in filings the Company makes with the United States Securities and Exchange Commission (SEC), available at: www.sec.gov, and on the Company's website, at: www.kushbottles.com.